var title_f19_60_20416="Infantile hemangioma - arrested growth";
var content_f19_60_20416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Infantile hemangioma with minimal or arrested growth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous patch with fine and coarse telangiectasias is present. Note the perilesional blanching and small proliferative component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20416=[""].join("\n");
var outline_f19_60_20416=null;
var title_f19_60_20417="Ventral cord syndrome";
var content_f19_60_20417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Location of lesion in ventral cord syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20417=[""].join("\n");
var outline_f19_60_20417=null;
var title_f19_60_20418="Patient information: Vaginal birth after cesarean delivery (The Basics)";
var content_f19_60_20418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83614\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18051\">",
"         Vaginal delivery (childbirth)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/10/30880\">",
"          Illustration of cesarean delivery",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"           Pregnancy terms",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/45/18131\">",
"            Different baby positions in the uterus",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/2/4131\">",
"         Patient information: How to tell when labor starts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/33/27155\">",
"         Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaginal birth after cesarean delivery (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaginal-birth-after-cesarean-delivery-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H873069720\">",
"      <span class=\"h1\">",
"       What is a vaginal birth after cesarean delivery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A vaginal birth after cesarean delivery is when a woman gives birth to a baby through her vagina after she had a baby by c-section in the past (",
"      <a class=\"graphic graphic_figure graphicRef59831 \" href=\"UTD.htm?17/40/18051\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63791 \" href=\"UTD.htm?30/10/30880\">",
"       figure 2",
"      </a>",
"      ). A c-section, also called a &ldquo;cesarean delivery,&rdquo; is surgery to get a baby out of a woman&rsquo;s uterus (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"       figure 3",
"      </a>",
"      ). A vaginal birth after cesarean delivery is called a &ldquo;VBAC&rdquo; for short.",
"     </p>",
"     <p>",
"      Years ago, doctors thought that after a woman had 1 c-section, she had to deliver all her other babies by c-section. That&rsquo;s because the uterus is cut open during a c-section. Even though the cut is stitched up and heals, doctors worried that the original cut could open up again when the uterus squeezed (contracted) during a future labor and delivery.",
"     </p>",
"     <p>",
"      But now doctors know that this rarely happens. Many women can safely have a vaginal delivery after a c-section.",
"     </p>",
"     <p>",
"      So a woman who had a c-section in the past now usually has a choice about how she will deliver her other babies. She can either:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Try to go through labor and have a vaginal delivery &ndash; Doctors call this a trial of labor after cesarean, called &ldquo;TOLAC&rdquo; for short. A trial of labor might work and end with a VBAC. But sometimes it doesn&rsquo;t work, and the woman needs another c-section to deliver her baby.",
"       </li>",
"       <li>",
"        Plan to have another c-section before labor starts",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H873069804\">",
"      <span class=\"h1\">",
"       What are the benefits of a VBAC?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The benefits of a VBAC include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A shorter stay in the hospital after giving birth",
"       </li>",
"       <li>",
"        Less pain and a shorter recovery time (usually)",
"       </li>",
"       <li>",
"        Fewer problems after the delivery &ndash; Women who have a c-section have a higher chance of getting a fever, infection, blood clot in the legs, or needing blood.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H873069819\">",
"      <span class=\"h1\">",
"       What problems might happen with a trial of labor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen with a trial of labor. But the problem doctors and midwives worry about most is the uterus tearing. This is an emergency. If it happens, a c-section needs to be done right away to deliver the baby.",
"     </p>",
"     <p>",
"      Plus, sometimes a trial of labor doesn&rsquo;t work. The labor might not progress normally and the baby might need to be delivered by c-section anyway. This can be upsetting and stressful for a woman.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H873069834\">",
"      <span class=\"h1\">",
"       What if I want to try and have a VBAC?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to try and have a VBAC, let your doctor or midwife know. Based on your individual situation, he or she will help you decide whether a trial of labor is a good choice for you.",
"     </p>",
"     <p>",
"      In general, a trial of labor has the highest chance of working when:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A woman had a vaginal delivery in the past (in addition to having a c-section).",
"       </li>",
"       <li>",
"        The first c-section was done because the baby was in a breech position. A breech position is when a baby&rsquo;s legs or buttocks (and not head) are closest to the vagina (",
"        <a class=\"graphic graphic_figure graphicRef72643 \" href=\"UTD.htm?17/45/18131\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For some women, a trial of labor is not recommended. This happens when:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The uterus was not cut open in the usual way during the previous c-section.",
"       </li>",
"       <li>",
"        The woman had many c-sections.",
"       </li>",
"       <li>",
"        A vaginal birth isn&rsquo;t safe for the mother or baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Plus, your doctor or midwife will only let you have a trial of labor in a hospital or center where a c-section could be done right away if needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H873069849\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=see_link\">",
"       Patient information: How to tell when labor starts (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=see_link\">",
"       Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/60/20418?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83614 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20418=[""].join("\n");
var outline_f19_60_20418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H873069720\">",
"      What is a vaginal birth after cesarean delivery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H873069804\">",
"      What are the benefits of a VBAC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H873069819\">",
"      What problems might happen with a trial of labor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H873069834\">",
"      What if I want to try and have a VBAC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H873069849\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18051\">",
"      Vaginal delivery (childbirth)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/10/30880\">",
"       Illustration of cesarean delivery",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"        Pregnancy terms",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/45/18131\">",
"         Different baby positions in the uterus",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=related_link\">",
"      Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_60_20419="Epidermolysis bullosa simplex - feet";
var content_f19_60_20419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions and bullae are present on the foot of this child with epidermolysis bullosa simplex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20419=[""].join("\n");
var outline_f19_60_20419=null;
var title_f19_60_20420="Fracture padding";
var content_f19_60_20420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Fracture padding in different sizes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20420=[""].join("\n");
var outline_f19_60_20420=null;
var title_f19_60_20421="Intermediate case 2 with answer";
var content_f19_60_20421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm with complete heart block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus rhythm with complete (third-degree) heart block. There is independent atrial (as shown by the P waves) and ventricular activity, with respective rates of 83 and 43 beats/min. The wide QRS complexes may represent a junctional escape rhythm with underlying bundle branch block or an idioventricular pacemaker.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20421=[""].join("\n");
var outline_f19_60_20421=null;
var title_f19_60_20422="Pyogenic granuloma gingival mucosa";
var content_f19_60_20422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma of the gingival mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucosal pyogenic granuloma in a 26 year-old woman in her fourth month of pregnancy. Excessive tissue growth impeding proper teeth contact and chewing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20422=[""].join("\n");
var outline_f19_60_20422=null;
var title_f19_60_20423="Isopropyl alcohol poisoning";
var content_f19_60_20423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Isopropyl alcohol poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Marco L A Sivilotti, MD, MSc, FRCPC, FACEP, FACMT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20423/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/60/20423/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isopropyl alcohol (isopropanol, 2-propanol, propan-2-ol) is commonly used as a disinfectant, antifreeze, and solvent, and typically comprises 70 percent of \"rubbing alcohol.\" People ingest isopropyl alcohol to become intoxicated (ie, ethanol substitute) or to harm themselves. When ingested, isopropyl alcohol functions primarily as a central nervous system (CNS) inebriant and depressant, and its toxicity and treatment resemble that of ethanol.",
"   </p>",
"   <p>",
"    Fatality from isolated isopropyl alcohol toxicity is rare, but can result from injury due to inebriant effects, such as untreated coma with airway compromise, or rarely, cardiovascular depression and shock following massive ingestion. Supportive care can avert most morbidity and mortality. It is important to differentiate isopropyl alcohol poisoning from methanol and ethylene glycol, which are more dangerous. Isopropyl alcohol does NOT cause an elevated anion gap acidosis, retinal toxicity (as does methanol), or renal failure (as does ethylene glycol). (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    This topic review will discuss the diagnosis and management of isopropyl alcohol intoxication. A summary table to facilitate emergency management is provided (",
"    <a class=\"graphic graphic_table graphicRef58793 \" href=\"UTD.htm?18/32/18956\">",
"     table 1",
"    </a>",
"    ). Discussions of other toxic alcohols and a general approach to the poisoned patient are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link\">",
"     \"Ethanol intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isopropyl alcohol is a sedative-hypnotic agent whose toxicity closely resembles that of ethanol, with which it shares strong structural similarity. Like ethanol, isopropyl alcohol's precise mechanism of action in the central nervous system (CNS) remains uncertain. Changes in membrane fluidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function, and interactions with neurotransmitter receptors, are believed to account for the CNS effects of alcohols and other simple hydrocarbons. There is a linear relationship between the molecular weight of alcohols and their sedative effects: as size increases so does sedation. Thus, isopropyl alcohol is marginally more potent than ethanol at comparable concentrations.",
"   </p>",
"   <p>",
"    In untreated animals, the median lethal dose lies between 4 and 8",
"    <span class=\"nowrap\">",
"     g/kg.",
"    </span>",
"    Many sources estimate the lethal dose to be 250 mL in humans (eg, less than 400 mL of a 70 percent solution). It is important to recognize that, with treatment, adults and children have survived much larger ingestions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isopropyl alcohol is metabolized by the alcohol dehydrogenase family of enzymes to acetone (",
"    <a class=\"graphic graphic_figure graphicRef50071 \" href=\"UTD.htm?10/63/11260\">",
"     figure 1",
"    </a>",
"    ). Following ingestion of at least several grams, the elimination of acetone is slower than its formation, and this metabolic end-product accumulates. Acetone itself is a mild CNS depressant and may exacerbate the CNS depression caused by isopropyl alcohol (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features of overdose'",
"    </a>",
"    below). It is also responsible for the marked ketosis that is present in most isopropyl alcohol ingestions (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Laboratory evaluation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Isopropyl alcohol does NOT cause an elevated anion gap acidosis, unlike the toxic alcohols methanol and ethylene glycol. Methanol and ethylene glycol are both primary alcohols, which are oxidized (via alcohol dehydrogenase and then aldehyde dehydrogenase) to carboxylic acids (formic acid in the case of methanol and glycolic, glyoxylic, and oxalic acids in the case of ethylene glycol). These acid metabolites cause the severe toxicity (ie, blindness, renal failure, and death) characteristic of methanol and ethylene glycol poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isopropyl alcohol is a secondary alcohol; as such, it is metabolized to a ketone (via alcohol dehydrogenase), rather than an aldehyde. Ketones cannot be oxidized to carboxylic acids. As a result, only very limited acidemia can occur; isopropyl alcohol is considerably less toxic than methanol or ethylene glycol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like ethanol, isopropyl alcohol is rapidly and completely absorbed following oral ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Peak serum concentration and clinical effects occur approximately one to two hours after ingestion. Substantial absorption and even toxicity are possible following dermal exposure, especially in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isopropyl alcohol is primarily metabolized to acetone via alcohol dehydrogenase, but the affinity of this enzyme family for isopropyl alcohol is approximately an order of magnitude less than for ethanol. Accordingly, small quantities of coingested ethanol effectively block metabolism of isopropyl alcohol and slow its serum elimination. In the absence of alcohol dehydrogenase (ADH) inhibition, the serum elimination half-life is approximately 2.5 to 8 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Acetone elimination is much slower, with a variable half-life of over 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. When ADH inhibitors (eg, ethanol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    ) are present, isopropyl alcohol clearance is markedly reduced, with a serum elimination half-life of 28 hours in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/14\">",
"     14",
"    </a>",
"    ]. Both isopropyl alcohol and acetone are rapidly cleared by hemodialysis, with clearance rates in excess of 200",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14877295\">",
"    <span class=\"h2\">",
"     Major effect and clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isopropyl alcohol manifests varying degrees of central nervous system (CNS) depression, ranging from inebriation with disinhibition, to sedation, to stupor and coma. These effects, due primarily to the parent alcohol (isopropyl alcohol), develop shortly after exposure, and peak within the first hour after ingestion. The absence of early symptoms excludes a significant isolated ingestion.",
"   </p>",
"   <p>",
"    Isopropyl alcohol's primary metabolite, acetone, causes less sedation. Steady improvement in the patient's level of consciousness is the expected clinical course. Of note, cross-tolerance in chronic alcoholics reduces the degree and duration of these effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to attempt to establish the product ingested, ideally by retrieving the original container and consulting product databases. In addition to ascertaining the timing and quantity of isopropyl alcohol ingested, clinicians should attempt to quantify any ethanol coingestion, to learn whether the ingestion was intentional, and, if intentional, to learn whether it was for recreational use or self-harm. Patients who have ingested large amounts of concentrated isopropyl alcohol may complain of nausea, vomiting, and abdominal pain. A discussion of how to approach the patient poisoned with unknown agents is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link&amp;anchor=H5#H5\">",
"     \"General approach to drug poisoning in adults\", section on 'Diagnosis of poisoning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=see_link\">",
"     \"Initial management of the critically ill adult with an unknown overdose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isopropyl alcohol poisoning causes an alteration in mental status similar to that seen in ethanol intoxication. Level of responsiveness, presence of disconjugate gaze, and ciliary reflex should be assessed in any patient with an alteration of mental status. A fruity breath odor is often perceptible, suggesting acetone accumulation. Following massive ingestion, signs of shock may be present, as may hematemesis, pulmonary edema, and hemorrhagic tracheobronchitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to exclude the possibility of methanol or ethylene glycol ingestion in any patient suspected of isopropyl alcohol poisoning. The early clinical course of all the toxic alcohols is quite similar, but important treatment differences exist. The absence of a high anion gap metabolic acidosis four to six hours post-ingestion enables the clinician to distinguish isopropyl alcohol from methanol or ethylene glycol intoxication in most cases. However, the presence of ethanol or the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    delays the appearance of such an acidosis in methanol and ethylene glycol poisoning, obscuring the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Starvation, alcoholic, and diabetic forms of ketoacidosis can also present with depressed mental status and ketosis. The presence of a metabolic acidosis helps to differentiate these entities from isopropyl alcohol overdose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=see_link\">",
"     \"Alcoholic and fasting ketoacidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common causes of ketosis include inborn errors of metabolism such as branched-chain ketonuria and propionic acidemia, salicylism, and ingestion of acetone itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14877310\">",
"    <span class=\"h2\">",
"     Tests to obtain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following tests should be obtained in all poisoned patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that affect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following tests and calculations should also be performed in patients suspected of ingesting isopropyl alcohol:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum isopropyl alcohol and acetone levels (or serum osmolality, if direct serum drug levels are unavailable) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Osmolal gap'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Basic electrolytes, with calculation of anion gap",
"     </li>",
"     <li>",
"      BUN and creatinine",
"     </li>",
"     <li>",
"      Serum and urine ketones",
"     </li>",
"     <li>",
"      Arterial or venous blood gas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serum isopropyl alcohol and acetone levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of isopropyl alcohol and acetone can be quantified directly using gas chromatography. The main use of such testing is to confirm the diagnosis, as treatment is largely supportive. However, many hospitals do not have rapid access to such testing.",
"   </p>",
"   <p>",
"    Confirmation of the diagnosis is important when uncertainty exists regarding the cause of a given patient's altered mental status, and is essential when another toxic alcohol may be present. Definitive serum levels may also quantify the amount of unmetabolized isopropyl alcohol and provide an estimate of the patient's tolerance. Serum concentrations of at least 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are necessary to cause a decreased level of consciousness. Isopropyl alcohol may be detected at low concentrations in the serum of patients with severe diabetic or alcoholic ketoacidosis, due to endogenous reduction of acetone to isopropyl alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Osmolal gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The osmolal gap provides important diagnostic information when quantitative serum testing for the toxic alcohols is not readily available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .) By comparing the measured plasma osmolality (determined by freezing point depression) to the calculated osmolarity, the clinician can infer the presence of an osmotically active, electrically neutral substance present at serum concentrations above 10",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (ie, at least 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    of isopropyl alcohol and acetone combined). Both isopropyl alcohol and acetone will raise the osmolal gap [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/8\">",
"     8",
"    </a>",
"    ]. The plasma osmolal gap cannot distinguish among isopropyl alcohol, methanol, and ethylene glycol poisoning, and so cannot be used to exclude ingestion of these more toxic alcohols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike methanol and ethylene glycol poisoning, neither a metabolic acidosis nor an elevated anion gap are expected after isopropyl alcohol ingestion. These findings should prompt the clinician to investigate alternative diagnoses. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link\">",
"     \"Approach to the child with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum and urine ketones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for serum and urine ketones using the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    reaction will be strongly positive in the presence of acetone. These tests are calibrated for ketonemia due to endogenous metabolism, and are thus very sensitive to the high acetonemia that follows a substantial ingestion of isopropyl alcohol. Low concentrations of serum ketones exclude any significant isopropyl alcohol exposure, provided at least",
"    <strong>",
"     two hours",
"    </strong>",
"    have transpired since ingestion, and alcohol dehydrogenase has not been blocked by coingested ethanol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/10\">",
"     10",
"    </a>",
"    ]. Some laboratories will measure &beta;-hydroxybutyrate concentrations when &ldquo;serum ketones&rdquo; are requested. Acetone is the predominant ketone generated by metabolism of isopropyl alcohol, and serum &beta;-hydroxybutryate concentrations remain low even following large ingestions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetone concentrations of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or greater can falsely elevate the serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, a high serum creatinine with a normal BUN and pH suggests the possibility of acetonemia due to isopropyl alcohol ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinician caring for a patient with altered mental status attributed to isopropyl alcohol must pursue alternative diagnoses if the patient fails to improve steadily over a few hours of observation. In such circumstances, additional testing, such as computed tomography (CT) of the head, lumbar puncture, and creatine kinase, may be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management begins with assessment and stabilization of the airway, breathing, and circulation. Clinicians should consider endotracheal intubation if there is doubt about the patient's ability to protect the airway and avoid aspiration. A summary table to facilitate emergency management is provided (",
"    <a class=\"graphic graphic_table graphicRef58793 \" href=\"UTD.htm?18/32/18956\">",
"     table 1",
"    </a>",
"    ). Advanced cardiac life support measures must be provided as required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with manifestations of significant intoxication (eg, stupor, hypotension) and those presenting immediately after ingestion should be closely observed and placed on cardiac and pulse oximetry monitors. Intravenous access should be obtained. Intravenous crystalloids are usually sufficient to correct any hypotension due to vasodilatation, but vasopressors may occasionally be required. Hypoglycemia should be corrected. As with ethanol overdose, most symptomatic patients recover within several hours of their ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for gastrointestinal (GI) decontamination in most cases of isolated isopropyl alcohol intoxication. Its rapid absorption after oral ingestion and its low toxicity make such interventions unnecessary. Gastric aspiration via a flexible nasogastric tube may be considered if it can be performed within one hour of a massive ingestion, as it may shorten the duration of coma, but this is not a critical intervention.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    may be useful for coingestants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Alcohol dehydrogenase (ADH) inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since acetone (the primary metabolite) is less toxic than isopropyl alcohol (the parent alcohol), there is no indication for ADH inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    or ethanol following isopropyl alcohol exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. Suspected methanol or ethylene glycol exposures should be managed accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Massive ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare patients with massive intentional ingestions may be hemodynamically unstable despite intravenous fluids and vasopressors. Serum isopropyl alcohol concentrations in such patients are generally over 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (80",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the plasma osmolal gap is generally over 100",
"    <span class=\"nowrap\">",
"     mosmol/L.",
"    </span>",
"   </p>",
"   <p>",
"    Clinicians",
"    caring for the rare patient with hemodynamic instability despite aggressive fluid resuscitation should consider hemodialysis, if it is readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. It should be emphasized that hemodialysis is almost never required. In most patients, the risks of hemodialysis outweigh the benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms from isopropyl alcohol manifest quickly. Therefore, patients with unintentional ingestions can be discharged after two hours if they remain asymptomatic and isopropyl alcohol is known to be the only substance involved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients ingesting isopropyl alcohol recreationally or as an ethanol substitute should be evaluated for alcohol abuse and managed accordingly. Patients who have deliberately ingested isopropyl alcohol to inflict harm should undergo assessment for concealed coingestions and psychiatric evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most exposures in children under the age of six years consist of accidental spills and sips. The irritant effects of high concentrations of isopropyl alcohol deter younger children from ingesting large amounts. Asymptomatic patients can be managed with home observation alone, assuming the product composition is known with certainty and the ingestion is estimated to be a mouthful or less [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20423/abstract/4\">",
"     4",
"    </a>",
"    ]. Clinicians should counsel caretakers about measures to prevent poisoning, with particular emphasis paid to proper storage of hazardous products and to avoiding the transfer of such materials from their original child-resistant containers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=see_link&amp;anchor=H376519128#H376519128\">",
"     \"Prevention of poisoning in children\", section on 'Anticipatory guidance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intentional recreational ingestions occur in adolescents with limited access to ethanol. Such exposures often happen in group settings, and product identification may be difficult. It is essential to rule out methanol or ethylene glycol ingestion, to locate all exposed patients, and to counsel such patients about substance abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107511044\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isopropyl alcohol is commonly ingested as an ethanol substitute, for deliberate self-harm, or in accidental exposures. It is commonly used as a disinfectant, antifreeze, and solvent, and typically comprises 70 percent of \"rubbing alcohol.\" When ingested, isopropyl alcohol functions primarily as a central nervous system (CNS) inebriant and depressant, and its toxicity and treatment resemble that of ethanol. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef58793 \" href=\"UTD.htm?18/32/18956\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmark of isopropyl alcohol metabolism is a marked ketonemia and ketonuria in the",
"      <strong>",
"       absence",
"      </strong>",
"      of metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and toxicology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isopropyl alcohol is rapidly and completely absorbed following oral ingestion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to establish with accuracy the product ingested. Clinicians must rule out ingestion of more toxic alcohols (methanol and ethylene glycol), which are associated with a high anion gap metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the basic studies obtained in all poisoned patients, the following laboratory tests and calculations should be obtained in the patient suspected of ingesting isopropyl alcohol (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum isopropyl alcohol and acetone levels",
"     </li>",
"     <li>",
"      or Serum osmolality (by freezing point depression), with calculation of osmolal gap,",
"      <strong>",
"       IF",
"      </strong>",
"      serum isopropyl alcohol level not readily available (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Osmolal gap'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Basic electrolytes, with calculation of osmolal gap (elevated in the setting of any toxic alcohol ingestion)",
"     </li>",
"     <li>",
"      BUN and creatinine (high serum creatinine with a normal BUN and pH suggest the possibility of acetonemia due to isopropyl alcohol ingestion)",
"     </li>",
"     <li>",
"      Serum and urine ketones (low concentrations of serum ketones by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      test exclude any significant isopropyl alcohol exposure,",
"      <strong>",
"       provided",
"      </strong>",
"      at least two hours have transpired since ingestion and alcohol dehydrogenase has not been blocked by ethanol or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arterial or venous blood gas (the presence of a metabolic acidosis or an anion gap is",
"      <strong>",
"       NOT",
"      </strong>",
"      expected with isopropyl alcohol intoxication and should prompt investigation of alternative diagnoses)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For isolated ingestions of isopropyl alcohol, there is no role for antidotal therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"      or ethanol. Gastrointestinal (GI) decontamination and hemodialysis are rarely necessary.",
"     </li>",
"     <li>",
"      Clinicians can manage an isopropyl alcohol overdose in similar fashion to an ethanol overdose. Clinicians should consider tracheal intubation if there is doubt about the patient's ability to protect their airway and avoid aspiration. Hypotension is treated with intravenous crystalloid, and vasopressors if necessary. Rapid recovery with supportive care alone is the expected course. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rare patients with massive intentional ingestions are hemodynamically unstable despite supportive treatment. Serum isopropyl alcohol concentrations in such patients are generally over 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (80",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and the osmolal gap generally over 100. Clinicians caring for these patients should obtain immediate nephrology consultation. We suggest treatment with hemodialysis for patients with persistent hemodynamic instability despite aggressive treatment with intravenous fluid and pressors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It should be emphasized that treatment with hemodialysis is almost never required. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Massive ingestion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic children with accidental ingestions can be managed with home observation alone, assuming the product composition is known with certainty and the ingestion is estimated to be a mouthful or less. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/1\">",
"      Trullas JC, Aguilo S, Castro P, Nogue S. Life-threatening isopropyl alcohol intoxication: is hemodialysis really necessary? Vet Hum Toxicol 2004; 46:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/2\">",
"      Freireich AW, Cinque TJ, Xanthaky G, Landau D. Hemodialysis for isopropanol poisoning. N Engl J Med 1967; 277:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/3\">",
"      Lacouture PG, Heldreth DD, Shannon M, Lovejoy FH Jr. The generation of acetonemia/acetonuria following ingestion of a subtoxic dose of isopropyl alcohol. Am J Emerg Med 1989; 7:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/4\">",
"      Stremski E, Hennes H. Accidental isopropanol ingestion in children. Pediatr Emerg Care 2000; 16:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/5\">",
"      Leeper SC, Almatari AL, Ingram JD, Ferslew KE. Topical absorption of isopropyl alcohol induced cardiac and neurologic deficits in an adult female with intact skin. Vet Hum Toxicol 2000; 42:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/6\">",
"      Vivier PM, Lewander WJ, Martin HF, Linakis JG. Isopropyl alcohol intoxication in a neonate through chronic dermal exposure: a complication of a culturally-based umbilical care practice. Pediatr Emerg Care 1994; 10:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/7\">",
"      Mydler TT, Wasserman GS, Watson WA, Knapp JF. Two-week-old infant with isopropanol intoxication. Pediatr Emerg Care 1993; 9:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/8\">",
"      Monaghan MS, Ackerman BH, Olsen KM, et al. The use of delta osmolality to predict serum isopropanol and acetone concentrations. Pharmacotherapy 1993; 13:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/9\">",
"      Pappas AA, Ackerman BH, Olsen KM, Taylor EH. Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. J Toxicol Clin Toxicol 1991; 29:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/10\">",
"      Gaudet MP, Fraser GL. Isopropanol ingestion: case report with pharmacokinetic analysis. Am J Emerg Med 1989; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/11\">",
"      Natowicz M, Donahue J, Gorman L, et al. Pharmacokinetic analysis of a case of isopropanol intoxication. Clin Chem 1985; 31:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/12\">",
"      Jones AW. Elimination half-life of acetone in humans: case reports and review of the literature. J Anal Toxicol 2000; 24:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/13\">",
"      Parker KM, Lera TA Jr. Acute isopropanol ingestion: pharmacokinetic parameters in the infant. Am J Emerg Med 1992; 10:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/14\">",
"      Bekka R, Borron SW, Astier A, et al. Treatment of methanol and isopropanol poisoning with intravenous fomepizole. J Toxicol Clin Toxicol 2001; 39:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/15\">",
"      Rosansky SJ. Isopropyl alcohol poisoning treated with hemodialysis: kinetics of isopropyl alcohol and acetone removal. J Toxicol Clin Toxicol 1982; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/16\">",
"      Abramson S, Singh AK. Treatment of the alcohol intoxications: ethylene glycol, methanol and isopropanol. Curr Opin Nephrol Hypertens 2000; 9:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/17\">",
"      Jones AE, Summers RL. Detection of isopropyl alcohol in a patient with diabetic ketoacidosis. J Emerg Med 2000; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/18\">",
"      Bailey DN. Detection of isopropanol in acetonemic patients not exposed to isopropanol. J Toxicol Clin Toxicol 1990; 28:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/19\">",
"      Blijenberg BG, Brouwer HJ. The accuracy of creatinine methods based on the Jaff&eacute; reaction: a questionable matter. Eur J Clin Chem Clin Biochem 1994; 32:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/20\">",
"      Linden CH. Unknown alcohol. Ann Emerg Med 1996; 28:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/21\">",
"      Zaman F, Pervez A, Abreo K. Isopropyl alcohol intoxication: a diagnostic challenge. Am J Kidney Dis 2002; 40:E12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/22\">",
"      Burkhart KK, Martinez MA. The adsorption of isopropanol and acetone by activated charcoal. J Toxicol Clin Toxicol 1992; 30:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20423/abstract/23\">",
"      Su M, Hoffman RS, Nelson LS. Error in an emergency medicine textbook: isopropyl alcohol toxicity. Acad Emerg Med 2002; 9:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 334 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20423=[""].join("\n");
var outline_f19_60_20423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14877295\">",
"      Major effect and clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14877310\">",
"      Tests to obtain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serum isopropyl alcohol and acetone levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum and urine ketones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Alcohol dehydrogenase (ADH) inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Massive ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107511044\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/334|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/63/11260\" title=\"figure 1\">",
"      Isopropyl alcohol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/32/18956\" title=\"table 1\">",
"      Isopropyl alcohol intoxication - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=related_link\">",
"      Initial management of the critically ill adult with an unknown overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=related_link\">",
"      Prevention of poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_60_20424="Facial features of a patient with acromegaly";
var content_f19_60_20424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68059%7EENDO%2F64652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68059%7EENDO%2F64652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial features of a patient with acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Facial aspect of a patient with acromegaly. The nose is widened and thickened, the cheekbones are obvious, the forehead bulges, the lips are thick and the facial lines are marked. The forehead and overlying skin is thickened, sometimes leading to frontal bossing.",
"    <br>",
"     (C, D) Mandibular overgrowth leads to prognathism, maxillary widening, teeth separation and jaw malocclusion.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008; 3:17. Copyright &copy; 2008 BioMed Central Ltd.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hands in acromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of the hands in a patient with acromegaly, which resulted in an increase in glove size and the need to remove rings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20424=[""].join("\n");
var outline_f19_60_20424=null;
var title_f19_60_20425="Chronic anticoagulation after acute coronary syndromes";
var content_f19_60_20425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic anticoagulation after acute coronary syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20425/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/60/20425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with an acute coronary syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H3#H3\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute coronary syndrome'",
"    </a>",
"    ), chronic oral anticoagulation is required to lower the risk of systemic (arterial) thromboembolism, such as those with atrial fibrillation, left ventricular systolic dysfunction or thrombus, or prosthetic heart valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=see_link&amp;anchor=H10#H10\">",
"     \"Left ventricular thrombus after acute myocardial infarction\", section on 'Prevention of formation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute coronary syndrome (ACS) patients are routinely treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ) to decrease the risk of recurrent events (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .) Thus, those who also require oral anticoagulation are discharged on triple oral anticoagulant therapy (TOAT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of whether chronic anticoagulant therapy reduces the risk of recurrent cardiovascular events, such as myocardial infarction (MI) or cardiac death, after ACS has been evaluated in clinical trials. The rationale for a potential role of chronic anticoagulant therapy in this setting is based on the following two pieces of information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high rates of recurrent ischemic events after ACS due, at least in part, to a persistent thrombotic risk within the coronary circulation. This thrombotic risk stems from heightened platelet reactivity, an increase in activity of some or all of the elements of the coagulation cascade, or both. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"       \"Overview of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The proven efficacy of long-term antithrombotic therapy with dual antiplatelet therapy in reducing recurrent ischemic events in most patients with an ACS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will focus on the potential role of oral anticoagulation to prevent recurrent ischemic events in patients with ACS. The use of chronic anticoagulant therapy in ACS patients who have clear indications for it will be addressed briefly here, but is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGIC PLAUSIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for possible benefit from chronic anticoagulant therapy for the prevention of recurrent ischemic events comes in part from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an ongoing thrombotic risk that may be due to progressive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is persistent elevation of markers of thrombin generation for as long as six months after ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial angioscopy of culprit plaques (after MI) shows persistence of thrombus at 1, 6, and 18 months (64, 5, and 12 percent respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link\">",
"       \"Pathology and pathogenesis of the vulnerable plaque\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vulnerable plaques are characterized by repeated plaque micro-ruptures, followed by subclinical thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In small angiographic follow-up studies of ACS patients treated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , lesion progression was significantly reduced in the warfarin group [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/1,5\">",
"       1,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Local synthesis of several functionally active coagulation proteins has been demonstrated in human atherosclerotic lesions. These proteins may be involved in atherogenesis, as indicated by increased thrombi-generating activity in early atherosclerotic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169516629\">",
"    <span class=\"h1\">",
"     PATIENTS WITHOUT OTHER INDICATIONS FOR CHRONIC ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence presented in this section",
"    <strong>",
"     does not",
"    </strong>",
"    support the use of chronic oral anticoagulant therapy to reduce the incidence of ischemic events after an ACS when patients (without other indications for anticoagulation) are managed with current recommendations for dual antiplatelet therapy (DAPT) and myocardial revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/6\">",
"     6",
"    </a>",
"    ]. The occasional ACS patient who cannot take a P2Y12 receptor blocker (eg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ) may benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;DAPT (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker) is recommended to most patients after ACS, with or without stent implantation. As there are no studies comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    plus DAPT to DAPT alone or to warfarin plus a single antiplatelet agent, the applicability to current practice of the studies presented below is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Keeping this limitation in mind, efficacy and safety outcomes have been evaluated in ACS patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone, and therapy with both. The available evidence suggests that combined therapy may reduce the risk of ischemic events compared to aspirin alone when the International Normalized Ratio (INR) is strictly maintained between 2.0 and 3.0. As combined therapy also increases the risk of bleeding compared to monotherapy, the benefit with warfarin is partially offset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H7#H7\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses of trials that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to aspirin alone came to a similar conclusion: among ACS patients at low or intermediate risk for bleeding, the benefits of adding warfarin to aspirin outweigh the bleeding risks",
"    <strong>",
"     only when the",
"    </strong>",
"    <strong>",
"     attained INR was 2.0 to 3.0",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The larger meta-analysis evaluated 14 trials with follow-up from three months to five years and involving over 25,000 patients with an ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/7\">",
"     7",
"    </a>",
"    ]. When evaluating the findings, it should be kept in mind that two of the major contributing trials, CHAMP and CARS, had median INR less than 2.0.",
"   </p>",
"   <p>",
"    The following findings were noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    compared to aspirin alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant difference in the overall risk of major adverse events (all cause death, nonfatal MI, and nonfatal thromboembolic stroke)",
"     </li>",
"     <li>",
"      A significant increase in major bleeding (odds ratio 1.77, 95% CI 1.47-2.13)",
"     </li>",
"     <li>",
"      In trials with a goal INR of 2.0 to 3.0, combination therapy was associated with a significant reduction in the risk of major adverse events (odds ratio 0.73, 95% CI 0.63-0.84)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10160367\">",
"    <span class=\"h3\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individual randomized trials included in the meta-analyses, the comparator therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , warfarin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or aspirin), the intensity of warfarin therapy, or both has varied [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/7-20\">",
"     7-20",
"    </a>",
"    ]. The intensity of warfarin therapy has varied from low (INR &le;1.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/20\">",
"     20",
"    </a>",
"    ], to moderate (INR 1.5 to 2.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/15,17-19\">",
"     15,17-19",
"    </a>",
"    ], to high (INR 2.5 to 4.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. In addition the trials varied significantly in the percent of patients with ST elevation MI, non-ST elevation MI, and unstable angina. These differences in trial design limit the ability to compare outcomes from one trial to another.",
"   </p>",
"   <p>",
"    The following trials account for most of the patients included in the above meta-analysis. In the first five, the majority of ACS patients had either ST elevation or non-ST elevation MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CHAMP trial randomly assigned 5059 patients to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone (81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or a combination of aspirin (81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , titrated to an INR of 1.5 to 2.5 (mean 1.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/18\">",
"       18",
"      </a>",
"      ]. After a 2.7 year follow-up there was no difference in mortality (17.3 versus 17.6 percent respectively), nonfatal infarction (13.1 versus 13.3 percent), or nonfatal stroke (3.5 versus 3.1 percent) between the two groups.",
"     </li>",
"     <li>",
"      The WARIS II trial randomly assigned 3630 patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (160",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      alone (target INR 2.8 to 4.2, mean attained INR 2.8), or combination therapy at lower dose (aspirin 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and target INR 2.0 to 2.5, mean attained INR 2.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/14\">",
"       14",
"      </a>",
"      ]. After a mean follow-up of four years, the incidence of the combined primary outcome of death, nonfatal reinfarction, or thromboembolic stroke was significantly less with combination therapy compared with aspirin alone (15 versus 20 percent, risk reduction 29 percent) and with warfarin alone compared to aspirin alone (16.7 versus 20.0 percent, risk reduction 19 percent).",
"     </li>",
"     <li>",
"      The ASPECT-2 trial randomly assigned 999 patients to one of three regimens: low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/day);",
"      </span>",
"      high intensity oral anticoagulation (target INR 3 to 4, mean attained value 3.2); or low dose aspirin plus moderate intensity anticoagulation (target INR 2 to 2.5, mean attained value 2.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/15\">",
"       15",
"      </a>",
"      ]. At a median follow-up of 12 months, the incidence of the primary end point of MI, stroke, or death was significantly lower in the two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus aspirin groups than in the aspirin alone group (5 versus 5 versus 9 percent, respectively). However, almost 20 percent of the warfarin and combined therapy groups discontinued treatment, and only about 40 percent of patients receiving warfarin remained in the therapeutic range.",
"     </li>",
"     <li>",
"      The CARS trial randomly assigned 8803 patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      160 mg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      3 mg with aspirin 80 mg, or warfarin 1mg with aspirin 80 mg daily. There was no significant difference in the combined primary outcome of reinfarction, non-fatal ischemic stroke, or cardiovascular death at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The LoWASA study randomly assigned 3300 patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      1.25 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 mg or aspirin 75 mg daily. After a median follow-up of 5 years, there was no significant difference in the combined primary outcome of cardiovascular death, reinfarction or stroke (28.1 versus 28.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The international OASIS-2 trial, randomly assigned 3712 patients (87 percent had unstable angina) to either oral anticoagulation (target INR of 2.5) in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or aspirin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/22\">",
"       22",
"      </a>",
"      ]. At five months, patients from countries in which there was good compliance to anticoagulation (INR &ge;2) had a significant reduction in the primary end point or cardiovascular death, myocardial infarction, or stroke (6.1 versus 8.9 percent, relative risk 0.68, 95% CI 0.48-0.95). No such benefit was seen in patients from countries with poor INR compliance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As pointed out in the discussion of the meta-analyses above, the inconsistent outcomes in the above trials may have resulted from either differing intensity of oral anticoagulant therapy or relatively high dropout rates in some.",
"   </p>",
"   <p>",
"    Two additional limitations question the applicability of these trials to current practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They were performed before the current era in which the great majority of patients with both non-ST elevation and ST elevation acute coronary syndromes are treated with an early invasive strategy using percutaneous coronary intervention with stenting (PCI) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They were performed before the current era in which most patients with an acute coronary syndrome are treated dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus a platelet P2Y12 receptor blocker. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two limitations render the evidence of benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (when added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) demonstrated in the meta-analyses above applicable to only a small portion of patients with ACS, as most individuals receive dual antiplatelet therapy and many receive revascularization",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169516837\">",
"    <span class=\"h2\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    is a direct thrombin inhibitor that has been approved for use for the prevention and treatment of venous and arterial thromboembolic disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H7479951#H7479951\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Other orally-active anticoagulants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    has not been evaluated for efficacy in the setting of ACS and thus we do not recommend its use. With regard to safety, the phase II RE-DEEM trial randomly assigned 1861 MI patients on dual antiplatelet therapy to dabigatran or placebo. There was a significant dose-dependent increase in the risk of major or clinically relevant minor bleeding during the six month treatment period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10157309\">",
"    <span class=\"h2\">",
"     Apixaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     Apixaban",
"    </a>",
"    is an oral factor Xa inhibitor that has been studied for the prevention of venous thromboembolism in postoperative patients and prevention of systemic embolic events in patients with atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H21#H21\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The APPRAISE-2 trial, which randomly assigned 7392 patients with an acute coronary syndrome (ACS) to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    5 mg twice daily or placebo in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or dual antiplatelet therapy, was stopped early due to a significant increase in the rate of major bleeding in the apixaban group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients included those with either MI or unstable angina (19 percent) within the previous seven days and at least two high risk features for a recurrent event (age &ge;65 years, diabetes mellitus, MI within 5 years, history of either cerebrovascular or peripheral artery disease, heart failure or a left ventricular ejection fraction &lt;40 percent, impaired renal function, or no revascularization for the index event).",
"   </p>",
"   <p>",
"    At a median follow-up of 241 days, the primary end point of cardiovascular death, MI, or ischemic stroke occurred in a similar percent of patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    and placebo groups (7.5 versus 7.9 respectively), while the primary safety outcome of Thrombolysis in Myocardial Infarction (TIMI) major bleeding occurred significantly more often in the group that received apixaban (1.3 versus 0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/25\">",
"     25",
"    </a>",
"    ]. These findings were consistent in all subgroups, including those stratified by use of revascularization (55 percent of patients underwent medical management without revascularization).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3770019\">",
"    <span class=\"h2\">",
"     Rivaroxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    is an oral factor Xa inhibitor that has been studied for the prevention of venous thromboembolism in postoperative patients and prevention of systemic embolic events in patients with atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H20#H20\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Rivaroxaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H358919860#H358919860\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ATLAS 2 ACS-TIMI 51 trial randomly assigned 15,526 patients with recent ACS to either twice-daily doses of either 2.5 mg or 5 mg (&ldquo;very low&rdquo; and &ldquo;low dose&rdquo;) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/26\">",
"     26",
"    </a>",
"    ]. These doses are one-quarter and one-half of the full anticoagulation dose. Patients with prior ischemic stroke or transient ischemic attack were excluded from the study.",
"   </p>",
"   <p>",
"    All patients were intended to receive dual antiplatelet therapy (DAPT) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    were not prescribed); 93 percent of patients ultimately received DAPT. The primary efficacy end point was a composite of death from cardiovascular causes, MI, or stroke. Approximately 50 percent of patients had STEMI, 25 percent NSTEMI, and 25 percent unstable angina. Less than 10 percent of patients were over the age of 75 years. More than 75 percent of patients had normal renal function.",
"   </p>",
"   <p>",
"    The following outcomes (comparing drug to placebo) were seen after a mean duration of treatment of 13.1 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      (both doses combined) significantly reduced the rate of primary efficacy end point (8.9 versus 10.7 percent; hazard ratio [HR] 0.84, 95% CI 0.74-0.96). These rates for the 2.5 and 5 mg doses of rivaroxaban were 9.1 and 8.8 percent, respectively.",
"     </li>",
"     <li>",
"      The rates of death of cardiovascular cause or any cause were significantly reduced with the 2.5 mg dose (2.7 versus 4.1 and 2.9 versus 4.5 percent, respectively). This survival benefit was not seen with the 5 mg dose. Both doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      significantly reduced the rate of stent thrombosis by about 31 percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      significantly increased the rate of TIMI major bleeding not related to coronary artery bypass grafting (2.1 versus 0.6 percent; HR 3.96, 95% CI 2.46-6.38). These rates for the 2.5 and 5 mg doses of rivaroxaban were 1.8 and 2.4 percent, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      , compared to placebo, significantly increased the rate of intracranial hemorrhage (0.6 versus 0.2 percent, respectively). The rates for the 2.5 and 5 mg doses were 0.4 and 0.7 percent. There was no significant increase in fatal bleeding (0.3 versus 0.2 percent, respectively); the rates for the 2.5 and 5 mg doses were 0.1 and 0.4 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    , particularly at the 2.5 mg twice daily dose, appears to improve outcomes in patients with recent ACS when added to dual antiplatelet therapy. It should be kept in mind that the level of anticoagulation achieved with either the 2.5 or 5 mg twice daily dose is less than that seen with the 15 or 20 mg once daily dose, as is used in patients with atrial fibrillation (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H358919860#H358919860\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the evidence of benefit demonstrated in ATLAS 2 ACS-TIMI 51, we do not recommend using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    (at any dose) to improve outcomes in patients with recent ACS for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not available at the lower dose formulations.",
"     </li>",
"     <li>",
"      The patient population who could be best treated with these lower doses needs to be better defined.",
"     </li>",
"     <li>",
"      In May of 2012, the United States Food and Drug Administration&rsquo;s Cardiovascular and Renal Drugs Advisory Committee voted against approval of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (to reduce the risk of recurrent cardiovascular events in ACS patients) due to concerns about missing data [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/27\">",
"       27",
"      </a>",
"      ]. A final decision by the United Stated Food and Drug Administration is pending.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7962934\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend chronic oral anticoagulation for ACS patients (without other indications) who are treated with current recommended therapies (including dual antiplatelet therapy) unless they meet other criteria for the use of anticoagulant therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    , at doses lower than those used for the prevention of thromboemboli in atrial fibrillation, has been shown to improve outcomes in this setting. However, we do not recommend its use to reduce the risk of recurrent cardiovascular events. (See",
"    <a class=\"local\" href=\"#H3770019\">",
"     'Rivaroxaban'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This recommendation is based on the fact that patients taking DAPT plus anticoagulant therapy have higher bleeding rates than those taking DAPT alone in addition to the fact that the evidence of benefit is mixed. In ACS patients taking dual antiplatelet therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has not been compared to placebo and full dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    had worse outcomes compared to placebo (APPRAISE). However, the results of ATLAS-2 TIMI 51, which compared two low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    to placebo, showed a significant reduction in the composite endpoint CV death, MI, and stroke with low dose rivaroxaban over placebo, as well as the rate of stent thrombosis, but with an increased risk of major bleeding and intracranial bleeding, but not fatal bleeding. A 2012 meta-analysis of seven heterogenous trials supports our recommendation but does not improve the quality of evidence provided above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some ACS patients will not receive dual antiplatelet therapy (DAPT), usually due to allergy to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or platelet P2Y12 receptor blocker. We suggest referral to a specialist (often an allergist) familiar with the management of these patients. There are several types of aspirin hypersensitivity syndromes, which can usually be distinguished by the nature of the patient&rsquo;s past reactions and the presence of certain characteristic underlying conditions (eg, chronic urticaria,&nbsp;asthma, chronic sinus disease). The different types of aspirin hypersensitivity and desensitizations protocols are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H15#H15\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H14#H14\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Hypersensitivity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=see_link\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who cannot receive dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus platelet P2Y12 receptor blocker, such as those who are allergic to one or both, we make the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those patients who cannot take a platelet P2Y12 receptor blocker and in whom those in whom the risk of bleeding (",
"      <a class=\"graphic graphic_table graphicRef75259 \" href=\"UTD.htm?38/14/39148\">",
"       table 1",
"      </a>",
"      ) due to long-term therapy with both antiplatelet and anticoagulant drugs is acceptable (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"       \"Therapeutic use of warfarin\", section on 'Bleeding'",
"      </a>",
"      ), we believe the addition of oral anticoagulant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is reasonable. This is based on a possible benefit from such therapy, as demonstrated in the meta-analyses discussed above in those patients in whom the INR on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy can be consistently between 2.0 and 3.0.",
"     </li>",
"     <li>",
"      When therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is chosen after ACS, warfarin should be stopped at one year (unless there is another indication for warfarin, such as atrial fibrillation), as the patient is then considered to have stable coronary heart disease.",
"     </li>",
"     <li>",
"      For the uncommon patient who cannot take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , options for antithrombotic therapy include a P2Y12 receptor blocker alone or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . These two strategies have not been compared. Our authors and reviewers recommend, based on their experience, a potent P2Y12 receptor blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      ) alone or warfarin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in combination for these patients. They have a preference for the former for the following reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Potent P2Y12 monotherapy avoids the inconvenience of routine international normalized ratio monitoring",
"     </li>",
"     <li>",
"      As P2Y12 receptor blockers are more effective at reducing the risk of cardiovascular events than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H16#H16\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Comparison to thienopyridines'",
"      </a>",
"      ), they do not feel compelled to add",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for efficacy as in patients who cannot take P2Y12 inhibitors as discussed above.",
"     </li>",
"     <li>",
"      Our authors and reviewers do not use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      in this situation as this combination likely has a greater risk of bleeding compared to warfarin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATIENTS WITH INDICATIONS FOR CHRONIC ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although oral anticoagulation is not indicated to decrease the risk of ischemic events after ACS (as discussed above), some patients with ACS require oral anticoagulation for other reasons. As most patients with ACS are discharged on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ), patients who require oral anticoagulation may be discharged on triple oral antithrombotic therapy (TOAT). It is important to note that trials of TOAT used clopidogrel, but not ticagrelor or prasugrel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following conditions, which were exclusion criteria from many of the randomized trials discussed above, are indications for the simultaneous use of chronic oral anticoagulation and dual antiplatelet therapy, which is referred to as triple oral antithrombotic therapy (TOAT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular (LV) thrombus or aneurysm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=see_link\">",
"       \"Left ventricular thrombus after acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=see_link\">",
"       \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link&amp;anchor=H5#H5\">",
"       \"Supraventricular arrhythmias after myocardial infarction\", section on 'Atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prosthetic heart valves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention or treatment of venous thromboembolism, such as deep vein thrombosis and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"       \"Anticoagulation in acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available evidence supports the use of TOAT as opposed to dual antiplatelet therapy (DAPT) to decrease the risk of major adverse cardiovascular events in patients with ACS and an indication for chronic oral anticoagulant therapy. This topic is discussed in detail elsewhere. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H3#H3\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'TOAT versus DAT'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally agree with recommendations made in the 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACCF/AHA)",
"    </span>",
"    guidelines on ST-Elevation MI and the 2012 focused update on Unstable",
"    <span class=\"nowrap\">",
"     Angina/Non-ST-Elevation",
"    </span>",
"    MI as well as the American College of Chest Physicians (ACCP) in the 2012 guideline on the primary and secondary prevention of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20425/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22846480\">",
"    <span class=\"h1\">",
"     BLEEDING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who require oral anticoagulant plus antiplatelet (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    P2Y12 receptor blocker) therapy, the bleeding risk is increased significantly compared to either therapy alone. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H7#H7\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10157891\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most acute coronary syndrome (ACS) patients are treated with dual antiplatelet therapy (DAPT), irrespective of whether an intracoronary stent was placed (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H35#H35\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Some of these patients require chronic anticoagulation to lower the risk of systemic thromboembolism (such as those with atrial fibrillation). Recommendations for the use of triple oral antithrombotic therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H24#H24\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For ACS patients who do not have an indication for chronic anticoagulant therapy, we make the following recommendations regarding the addition of oral anticoagulant therapy to antiplatelet therapy to reduce the risk of subsequent ischemic events after an ACS (see",
"    <a class=\"local\" href=\"#H169516629\">",
"     'Patients without other indications for chronic anticoagulation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients taking dual antiplatelet therapy (DAPT), we recommend not adding oral anticoagulant therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7962934\">",
"       'Summary'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A few ACS patients may appear to not be candidates for DAPT due to allergy to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or platelet P2Y12 receptor blocker. These patients should be referred to a specialist (often an allergist) for an attempt at desensitization. For these",
"      <strong>",
"      </strong>",
"      patients taking antiplatelet monotherapy, we make the following recommendations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      but unable to take a P2Y12 receptor blocker and who are at low to intermediate bleeding risk (",
"      <a class=\"graphic graphic_table graphicRef75259 \" href=\"UTD.htm?38/14/39148\">",
"       table 1",
"      </a>",
"      ), we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to aspirin monotherapy for one year (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This recommendation applies only if the INR can be maintained within the range of 2.0 to 3.0. (See",
"      <a class=\"local\" href=\"#H7962934\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients taking P2Y12 receptor blocker but who are unable to take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <strong>",
"      </strong>",
"      we suggest antithrombotic monotherapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (no oral anticoagulant added to either) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"      In patients for whom ticagrelor and prasugrel are not available,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is a reasonable alternative.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H7962934\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/1\">",
"      Williams MJ, Morison IM, Parker JH, Stewart RA. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997; 30:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/2\">",
"      Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/3\">",
"      Ueda Y, Asakura M, Yamaguchi O, et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 2001; 38:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/4\">",
"      Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/5\">",
"      Williams MJ, Stewart RA. Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. Int J Cardiol 1999; 69:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/6\">",
"      Husted SE, Ziegler BK, Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J 2006; 27:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/7\">",
"      Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/8\">",
"      Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/9\">",
"      A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/10\">",
"      Breddin K, Loew D, Lechner K, et al. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980; 62:V63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/11\">",
"      Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994; 343:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/12\">",
"      Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/13\">",
"      A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980; 2:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/14\">",
"      Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/15\">",
"      van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/16\">",
"      Meijer A, Verheugt FW, Werter CJ, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 1993; 87:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/17\">",
"      Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ 1996; 313:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/18\">",
"      Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/19\">",
"      Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002; 106:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/20\">",
"      Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997; 350:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/21\">",
"      Herlitz J, Holm J, Peterson M, et al. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004; 25:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/22\">",
"      Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol 2001; 37:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/23\">",
"      Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/24\">",
"      Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/25\">",
"      Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/26\">",
"      Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medscape.com/viewarticle/764433?src=mp&amp;spon=2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/28\">",
"      Kom&oacute;csi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/29\">",
"      2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/30\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/31\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20425/abstract/32\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 101 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20425=[""].join("\n");
var outline_f19_60_20425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10157891\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGIC PLAUSIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H169516629\">",
"      PATIENTS WITHOUT OTHER INDICATIONS FOR CHRONIC ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10160367\">",
"      - Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169516837\">",
"      Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10157309\">",
"      Apixaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3770019\">",
"      Rivaroxaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7962934\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATIENTS WITH INDICATIONS FOR CHRONIC ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22846480\">",
"      BLEEDING RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10157891\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/14/39148\" title=\"table 1\">",
"      HAS-BLED risk score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=related_link\">",
"      Pathology and pathogenesis of the vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_60_20426="Management of superficial esophageal cancer";
var content_f19_60_20426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of superficial esophageal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20426/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20426/contributors\">",
"     Cameron D Wright, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20426/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20426/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/60/20426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/60/20426/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/60/20426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of esophageal cancer has evolved over the last two decades. Although the most marked change is a reversal in the ratio of squamous cell cancers to adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/1\">",
"     1",
"    </a>",
"    ], there has also been a shift in stage distribution. The incidence of superficial esophageal cancer (invading no deeper than the submucosa) is increasing, particularly in Asian countries where screening for upper digestive tract cancers is common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. A similar trend has been seen in the United States and attributed, at least in part, to routine endoscopic surveillance for malignancy and high-grade dysplasia (HGD) in patients with Barrett's esophagus, a complication of longstanding gastroesophageal reflux disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=see_link\">",
"     \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For many years, the standard treatment for both HGD and superficial esophageal cancer has been esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/2,8-12\">",
"     2,8-12",
"    </a>",
"    ]. High cure rates were achieved but at the cost of treatment-related morbidity and mortality. Endoscopic approaches to definitive therapy (eg, endoscopic resection [ER], photodynamic therapy [PDT], laser therapy, and argon plasma coagulation [APC]) have increasingly been used in this country, following encouraging early reports from Japan and Europe. However, these techniques are only appropriate for patients who have a very low risk of lymph node metastases or who are poor candidates for esophageal surgery.",
"   </p>",
"   <p>",
"    This topic review will focus on treatment strategies for superficial esophageal cancer. The epidemiology, clinical presentation, diagnosis and staging of esophageal cancer, surgical techniques for esophagectomy, and combined modality approaches for the treatment of muscle-invasive disease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical component of choosing the appropriate management strategy for a superficial esophageal cancer is an accurate assessment of disease extent. Submucosal involvement is the most important prognostic determinant for early esophageal cancers because the presence of lymphatic vessels within the submucosa facilitates dissemination of cancer cells. Thus an accurate assessment of tumor extent, often with the utilization of high frequency endoscopic ultrasound, is needed to direct therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathologic subclassification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early esophageal cancers are those that are classified as Tis (high-grade dysplasia, which includes all noninvasive neoplastic epithelial that was formerly called carcinoma in situ) or T1 tumors, which are split into T1a and T1b subcategories depending on the depth of invasion (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/13\">",
"     13",
"    </a>",
"    ]. However, this classification by itself is inadequate to distinguish differences in lymph node involvement among T1a versus T1b esophageal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more comprehensive subclassification scheme has been proposed for early esophageal cancers and is useful for determining prognosis and selecting treatment (",
"    <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. According to this classification, mucosal tumors are divided into three types based upon the depth of invasion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M1 &mdash; Limited to the epithelial layer",
"     </li>",
"     <li>",
"      M2 &mdash; Invades the lamina propria",
"     </li>",
"     <li>",
"      M3 &mdash; Invades into but not through the muscularis mucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    M1 tumors correspond to the Tis stage in the AJCC stage definition, while both M2 and M3 tumors would be considered T1a lesions.",
"   </p>",
"   <p>",
"    Tumors invading the submucosa are subclassified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SM1 &mdash; Penetrates the shallowest one-third of the submucosa",
"     </li>",
"     <li>",
"      SM2 &mdash; Penetrates into the intermediate one-third of the submucosa",
"     </li>",
"     <li>",
"      SM3 &mdash; Penetrates the deepest one-third of the submucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these subcategories would be considered T1b disease according to the AJCC stage definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of lymph node metastases in published series of patients with early esophageal cancer, stratified according to depth of invasion, is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef64478 \" href=\"UTD.htm?13/7/13437\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/8-11,15-19\">",
"     8-11,15-19",
"    </a>",
"    ]. The following conclusions can be drawn from these data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there are fewer data on superficial adenocarcinomas, rates of nodal metastases are no higher [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/17\">",
"       17",
"      </a>",
"      ] than with squamous cell cancers, which have been more extensively investigated.",
"     </li>",
"     <li>",
"      M1 and M2 tumors are not associated with lymph node metastases and hence are well suited to endoscopic treatment.",
"     </li>",
"     <li>",
"      The risk of nodal metastases with M3 tumors is zero in many studies, but as high as 12 percent in others (",
"      <a class=\"graphic graphic_table graphicRef64478 \" href=\"UTD.htm?13/7/13437\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients with evidence of lymphatic invasion are the most likely to harbor lymph node metastases. In a report of 464 consecutive patients with superficial esophageal cancer who underwent radical esophagectomy with node dissection, only four of the 38 patients with M3 lesions and no lymphatic invasion had lymph node metastases, whereas five of the 12 patients with lymphatic invasion were found to have nodal metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/21\">",
"       21",
"      </a>",
"      ]. Thus, for patients with M3 tumors without evidence of lymphatic invasion, endoscopic therapy is also a reasonable strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All submucosal tumors have a substantial risk of lymph node metastases. Endoscopic mucosal resection should be avoided in these patients. Esophagectomy with therapeutic lymphadenectomy may be potentially curative (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Esophagectomy'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to depth of invasion, other tumor features that may impact on the risk of lymph node metastases are macroscopic appearance of the lesion (flat-type versus non-flat [elevated, depressed, or ulcerated]) and the presence of lymphovascular invasion, but not the histologic grade of differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/9,15,24-26\">",
"     9,15,24-26",
"    </a>",
"    ]. In the Shimada series described above, the risk of positive nodes was significantly higher for non-flat type lesions as compared to flat-type lesions (37 versus 17 percent, respectively), while it was no different among patients with histologically poorly differentiated versus differentiated lesions (31 and 39 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Accuracy of EUS in the staging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the depth of invasion is an important indicator of the risk for nodal metastases in patients with superficial esophageal cancer. At present, endoscopic ultrasound (EUS) is the most accurate noninvasive method to assess depth of invasion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73301 \" href=\"UTD.htm?37/9/38035\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24597?source=see_link\">",
"     \"Endoscopic ultrasound: Anatomy of the normal esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The accuracy of EUS for T staging of superficial tumors has been controversial. While an earlier meta-analysis suggested that EUS may not be as accurate for T staging in patients with early esophageal cancer compared with those with more advanced tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/27\">",
"     27",
"    </a>",
"    ], a subsequent larger meta-analysis found that EUS was accurate for staging T1a and T1b tumors, with an area under the receiver operating characteristic curve of 0.93 to 0.96 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the EUS identifies esophageal cancer that invades the muscularis mucosa or if there is evidence of lymph node involvement, then surgical therapy is often recommended. On the other hand, if the EUS identifies only mucosal disease and the patient is potentially eligible for endoscopic treatment, an endoscopic mucosal resection is then performed to precisely define the depth of invasion. The pathology result from the endoscopic mucosal resection (particularly the presence or absence of lymphovascular invasion) can be used to guide the final decision as to whether endoscopic therapy alone is sufficient or if surgery should be recommended.",
"   </p>",
"   <p>",
"    This approach has been questioned by some who suggest that EUS should not be used to determine which patients should go to surgery and that instead all patients with an apparently superficial esophageal cancer should undergo careful endoscopic examination with endoscopic resection without EUS. This position is supported by a retrospective study that included 131 patients with early esophageal or cardia neoplasia (primarily adenocarcinoma arising from Barrett&rsquo;s esophagus) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients underwent EUS and endoscopic resection (ER) for staging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EUS findings were suggestive of submucosal invasion or lymph node metastases in 26 patients (20 percent). Of note, EUS-guided FNA was undertaken in 6 of 12 patients with suspicious lymph nodes, none of whom were shown to have spread from the esophageal cancer. In 10 of the 26 patients with an abnormal EUS, the ER specimen did not show risk factors for lymph node metastases (ie, submucosal invasion [or T1m3 cancer for patients with squamous cell dysplasia], poorly differentiated cancer, lymphovascular infiltration, or tumor involvement at the deep resection margin). Surgical resection was not performed, and no patient developed recurrent neoplasia during follow-up (median 30 to 42 months).",
"   </p>",
"   <p>",
"    Among the 105 patients with normal EUS findings (ie, no suspicion of deep mucosal invasion or lymphadenopathy), 25 (24 percent) had ER specimens that showed risk factors for lymph node metastases. Subsequent surgery showed 19 patients with submucosal invasion and six with high-grade histology or vascular infiltration.",
"   </p>",
"   <p>",
"    Based upon these findings, the authors concluded that EUS findings have no clinical impact on the workup of early esophageal neoplasia and that EUS findings alone are not sufficient to refer a patient for surgery without confirmation by ER.",
"   </p>",
"   <p>",
"    Given that ER provides more precise histologic staging, EUS appears to be of diminishing importance in the diagnostic workup of a superficial esophageal cancer. Upfront EUS is probably unnecessary if endoscopic inspection suggests that ER is feasible. If the diagnostic ER confirms a low-risk neoplasm, the additional impact of EUS remains questionable. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ESOPHAGECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the emergence of endoscopic techniques, esophagectomy was the treatment of choice for superficial esophageal cancers. The potential advantages of esophagectomy include precise pathologic staging information, the permanent removal of all Barrett's mucosa at risk to develop a malignant focus, and treatment is definitive, without the need for posttreatment surveillance or salvage therapy in the event of a recurrence. Among the disadvantages are an average ten day hospital stay, a substantial risk of major complications, a small but real risk of perioperative death (about 2 percent in high-volume centers, see below), a recovery period that can take several months, and the potential for long-term problems with swallowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The volume-performance relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, esophagectomy was associated with perioperative morbidity and mortality rates that were among the highest of all standard cancer operations as well as other major procedures such as cardiac or vascular surgery. As such, it earned a reputation as high-risk surgery, prompting reluctance on the part of physicians to refer patients for resection, particularly if they had early-stage disease.",
"   </p>",
"   <p>",
"    However, patients who undergo esophagectomy by experienced surgeons at hospitals that perform large numbers of procedures have lower perioperative mortality rates and better early clinical outcomes than those who undergo resection at lower volume institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/30-38\">",
"     30-38",
"    </a>",
"    ]. In the most-often quoted study on the volume-performance relationship for esophagectomy, the Medicare claims database for 1998 and 1999 was analyzed to determine the relationship between surgeon and hospital volume and operative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/30\">",
"     30",
"    </a>",
"    ]. In general, these were elderly patients with significant comorbidity and usually advanced disease. Perioperative mortality rates were significantly related to surgeon volume: they were 19, 13, and 9 percent for surgeons performing fewer than two, between two and six, and more than six esophagectomies per year, respectively (p&lt;0.001). This effect held true even among low-volume surgeons working in high-volume hospitals.",
"   </p>",
"   <p>",
"    There was also a significant correlation between hospital volume and perioperative mortality. When compared to the lowest volume hospitals (fewer than two procedures annually), the adjusted odds ratio for mortality for patients treated at the highest volume hospitals (more than 19 procedures annually) was 0.36 (95% CI 0.26 to 0.50). A second series found that high-volume hospitals were able to reduce their esophagectomy-related mortality over time (from 11 to 7.5 percent, p = 0.003), presumably from increasing experience with the procedure, while low-volume hospitals could not (procedure-related mortality rates were 15.3 versus 14.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/31\">",
"     31",
"    </a>",
"    ]. Other reports document lower complication rates in high-volume hospitals and more successful management of complications compared with low-volume hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis sought to define the number of esophagectomies needed for a center to achieve an acceptably low mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/33\">",
"     33",
"    </a>",
"    ]. Hospitals that performed more than 20 resections per year had a perioperative mortality rate of only 4.9 percent, and the odds ratio of death for hospitals performing more than 20 resections per year compared to a lesser number was 0.43 (95% CI 0.31 to 0.58). Thus, a minimum of 20 esophagectomies per year has become a benchmark, with most large high-volume centers now reporting perioperative mortality rates in the range of 1 to 4 percent.",
"   </p>",
"   <p>",
"    In summary, the weight of evidence supports the view that \"practice makes perfect\" in this high-risk, demanding operation. As such, the optimal management strategy is to refer patients needing esophagectomy to a high-volume center that specializes in esophageal cancer care. Nevertheless, a large proportion of esophagectomies in the US are still performed in low volume centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several published reports detail outcomes from esophagectomy for superficial esophageal cancer (",
"    <a class=\"graphic graphic_table graphicRef59698 \" href=\"UTD.htm?12/60/13261\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/2,8-12,14,39-45\">",
"     2,8-12,14,39-45",
"    </a>",
"    ]. However, interpretation of these data is limited by high perioperative morbidity and mortality rates in many series, attributable both to the long time period over which cases were collected and to the volume-performance issues discussed above. Nonetheless, these reports provide an approximation of expected outcomes after esophagectomy in patients with superficial cancers. The following conclusions can be drawn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Results are much better than standard surgical series of esophagectomy for muscle-invasive cancers, where three to five-year survival rates are 25 to 30 percent. Likewise, recurrence rates are relatively low, with most patients dying of other causes, again unlike standard surgical series. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is a clear difference in outcomes when mucosal and submucosal cancers are compared. This is best illustrated by the series by Westerterp and colleagues which analyzed recurrence-free survival according to depth of invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/11\">",
"       11",
"      </a>",
"      ]. There was only one local recurrence among 79 patients with M1, M2, M3, or SM1 tumors (",
"      <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"       figure 1",
"      </a>",
"      ) (five-year recurrence-free survival 97 percent). Recurrence rates were higher among those with SM2 and SM3 tumors (8 of 41 patients, five-year recurrence-free survival 57 percent). In this series, 19 patients already had nodal metastases at the time the superficial cancer was diagnosed; their outcomes were significantly worse after resection than those for patients without nodal metastases (five-year recurrence-free survival 33 versus 94 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information can be derived from series of patients undergoing esophagectomy for a biopsy diagnosis of HGD (sometimes called high-grade esophageal intraepithelial neoplasia or HGIN) in the setting of Barrett's esophagus. Typically, these patients have not had EUS or endoscopic resection, so they are often understaged. The high incidence of finding invasive cancer in the resected specimen (about 40 percent) has led many surgeons to recommend esophagectomy for fit patients with a diagnosis of HGD, although others suggest endoscopic surveillance every three months until invasive cancer is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/12,40-42,46-50\">",
"     12,40-42,46-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outcomes from esophagectomy can be illustrated in a series of 86 patients treated for HGD at a single institution, 49 treated by esophagectomy, and 47 by endoscopic techniques (photodynamic therapy [n = 42] or endoscopic mucosal resection [n = 5]) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/46\">",
"     46",
"    </a>",
"    ]. Invasive adenocarcinoma was present in 37 percent of the specimens. The mortality of esophagectomy was 2 percent, and there were three recurrences (6 percent), compared to seven in the endoscopically treated group (15 percent). Among surgically treated patients, the five-year survival rate was 83 percent, and the disease-specific survival was 94 percent. When the analysis was limited to patients found to have either HGD alone or invasive cancer limited to the mucosa or submucosa and uninvolved lymph nodes (n = 41), the disease-specific five-year survival rate was 100 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Impact on health-related quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagectomy can result in long-term symptoms such as dysphagia, cough, and reflux, all of which may impair health-related quality of life (HR-QOL) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. However, much of the data are in patients who have undergone esophagectomy for invasive esophageal cancer, many of whom have a low performance status at the time of surgery due to progressive dysphagia and weight loss.",
"   </p>",
"   <p>",
"    HR-QOL in patients undergoing esophagectomy for high-grade dysplasia (noninvasive neoplastic epithelia) was explored in a cohort study of 36 patients treated at a single institution over a 12-year period who were found to harbor invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients were contacted by mail postoperatively, and 28 completed self-administered surveys to assess current gastrointestinal symptoms and HR-QOL parameters.",
"   </p>",
"   <p>",
"    The minor and major (cervical anastomotic or thoracic duct leak) perioperative complication rates were 44 and 11 percent, respectively, and no patient died within 30 days of surgery. On the gastrointestinal symptom questionnaire, 22 patients (79 percent) reported their perception of eating as \"normal\" or \"insignificantly impaired\". However, 93 percent needed to eat more slowly postoperatively, 18 percent had heartburn, and dysphagia or regurgitation were reported by 54 and 54 percent, respectively. Despite this, when the results of the Medical Outcomes Study 36-item Short Form Health Survey were compared to norm-based values for age- and sex-matched controls from the 1998 US general population, the postesophagectomy population equaled or exceeded HR-QOL scores in seven of eight domains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Less radical approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Minimally invasive esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience in minimally invasive techniques including laparoscopic vagal nerve sparing surgery for esophageal cancer resection is widening. The potential advantages of this approach relative to open esophagectomy include smaller incisions, less intraoperative blood loss, a reduction in some postoperative complications, decrease in intensive care and overall hospital stay, and better preservation of postoperative pulmonary function. Areas of controversy include the adequacy of the surgical margins and lymph node dissection, and whether comparable long-term outcomes can be achieved as compared to open esophagectomy.",
"   </p>",
"   <p>",
"    The available literature is limited by the lack of prospective trials comparing minimally invasive versus open esophagectomy, and there are few reports that address oncologic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/14\">",
"     14",
"    </a>",
"    ] . Additional data, particularly regarding complications and long-term oncologic outcomes, are needed before it can be concluded that results are comparable to those seen with open surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/54\">",
"     54",
"    </a>",
"    ]. This subject is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vagal-sparing esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low rate of nodal positivity among patients with intramucosal esophageal adenocarcinoma has prompted some to suggest that a less morbid type of esophagectomy, a vagal-sparing esophagectomy, is preferred over radical esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/55\">",
"     55",
"    </a>",
"    ]. Because lymphadenectomy is not performed and the vagal trunks are not divided during esophagectomy, this approach reduces the physiologic impact of esophagectomy, eliminating the need for pyloroplasty and minimizing the risk of dumping and postvagotomy diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In at least one report, oncologic outcomes among 49 patients undergoing vagal-sparing esophagectomy were comparable to those of 51 patients who had a transhiatal or en bloc esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/55\">",
"     55",
"    </a>",
"    ]. Compared with transhiatal resection, patients who had a vagal-sparing procedure had significantly fewer postoperative complications (21 versus 56 percent), a shorter hospital stay (11 versus 16 days), and a reduced incidence of postvagotomy diarrhea (5 versus 27 percent) and dumping syndrome (10 versus 21 percent). In contrast, the prevalence of regurgitation (63 versus 45 percent) and delayed gastric emptying (16 percent in both groups) were similar.",
"   </p>",
"   <p>",
"    This approach is not appropriate for patients with submucosal invasion because of the need for lymph node dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Limited esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a small subset of patients with small very early cancers right at the GEJ, a limited resection of the distal esophagus and proximal stomach with jejunal interposition and a regional lymphadenectomy may provide a less morbid approach to total esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, experience with this approach is limited, and close attention to technical details is needed to avoid complications, poor functional results, and the need for reintervention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/59\">",
"     59",
"    </a>",
"    ]. Limited resection is almost never undertaken in the US, where the standard approach is to perform a total esophagectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagectomy is the treatment of choice for fit patients with superficial esophageal cancers invading the submucosa (",
"    <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"     figure 1",
"    </a>",
"    ). Although the preferred treatment for intramucosal superficial cancers has traditionally been surgery, endoscopic mucosal resection can be considered in selected patients where expertise in endoscopic mucosal resection is available. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Endoscopic mucosal resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because outcomes are directly related to surgeon as well as institutional experience, patients needing esophagectomy should be referred to a high-volume center that specializes in esophageal cancer care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aims of endoscopic therapy are to preserve the integrity of the esophagus while providing a potentially curative option for superficial cancers. The available options are endoscopic resection (ER), and various ablation methods including photodynamic therapy (PDT), argon plasma coagulation (APC), radiofrequency ablation (RFA), and laser therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endoscopic mucosal resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;With ER, the neoplastic epithelium is excised rather than ablated, thus allowing for a definitive histologic diagnosis. A variety of techniques are available, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An understanding of the efficacy of ER for management of superficial esophageal cancer is evolving. Most observational series contain a small number of patients with both HGD and superficial cancer (mainly treated at two large centers), and the duration of follow-up is limited. The largest of these included 349 patients with Barrett's esophagus and either high grade dysplasia (n=61) or mucosal adenocarcinoma (n=288) who underwent ER [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/60\">",
"     60",
"    </a>",
"    ]. Most were treated with ER alone (n=279), but others received PDT (n=55), both ER and PDT (n=13), or APC (n=2). At a mean follow-up of 63.1 months, a complete response was found in 96.6 percent (337) of treated patients. Surgery was needed in 3.7 percent after endoscopic therapy failed. Recurrences were noted in 21.5 percent (n=74), but no patient died from esophageal cancer.",
"   </p>",
"   <p>",
"    These and other data on the efficacy of ER for Barrett's related HGD and early cancer are described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link&amp;anchor=H21#H21\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Endoscopic resection versus surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized trials are not available, the available evidence suggests that, in appropriately selected patients with early stage esophageal cancer (disease limited to the mucosa), the long-term outcomes with ER are comparable to surgical treatment, with fewer complications, but a higher recurrence rate (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathologic subclassification'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    Several retrospective comparisons are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes of ER and esophagectomy were compared among 114 patients with superficial esophageal cancer limited to the mucosa, 38 of whom underwent resection and 76 ER with argon-plasma coagulation of the remaining nondysplastic Barrett&rsquo;s [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/61\">",
"       61",
"      </a>",
"      ]. As expected, procedure-related morbidity and mortality rates were higher after esophagectomy. At a median follow-up of 4.6 years, there was one recurrence and four metachronous neoplasms after ER (overall recurrence rate 6.6 percent) versus none after surgery. However, repeat endoscopic treatment was possible in all patients and the long-term complete response rates were similar after ER and esophagectomy (98.7 and 100 percent, respectively).",
"     </li>",
"     <li>",
"      Another retrospective series examined long-term outcomes of 178 patients with mucosal (T1a) esophageal cancers, 132 treated by ER and 46 by surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/62\">",
"       62",
"      </a>",
"      ]. Of the patients treated endoscopically, 57 had photodynamic therapy in addition to ER (see below). The cumulative mortality was no higher in the endoscopically treated group (17 versus 20 percent with esophagectomy). At a median follow-up of 43 months, 12 percent of the endoscopically treated group recurred, and all were successfully treated (with ER, esophagectomy, or chemoradiotherapy) without an adverse impact on overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another source of information on the comparative efficacy of ER and esophagectomy for early esophageal cancer comes from an analysis of the population-based National Cancer Institute SEER registry [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/63\">",
"     63",
"    </a>",
"    ]. The review included 742 patients diagnosed with Tis or T1 nonsquamous and squamous cell-type esophageal cancer between 1998 and 2003, and reported to the SEER registry. Endoscopic treatment (ER alone in two-thirds) was given to 99 patients (13 percent), while the remainder (n=643) were managed by surgical resection. In a Cox proportional hazards model, the relative hazard for esophageal cancer-specific mortality in the patients treated by endoscopic therapy was no different from the surgical group (relative hazard 0.89, 95% CI 0.51 to 1.56, p=0.68).",
"   </p>",
"   <p>",
"    Complications of ER include acute perforations and bleeding, and delayed esophageal strictures. Post-ER bleeding (typically managed by endoscopic methods) is reported in 3 to 33 percent of cases and may be more frequent if saline is not used to lift the lesion before removal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link&amp;anchor=H22#H22\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A drawback of ER monotherapy for HGD or early esophageal cancer in Barrett's esophagus has been the high rate of",
"    <span class=\"nowrap\">",
"     recurrent/metachronous",
"    </span>",
"    lesions during follow-up in some series (as high as 22 percent in the series described above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/60\">",
"     60",
"    </a>",
"    ]). Some argue that the majority of patients who recur can be salvaged with repeat ER, and they do not die of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/23,61,62,65\">",
"     23,61,62,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two endoscopic approaches are used for ER. The first is endoscopic mucosal resection (EMR), which involves snare resection of dysplastic lesion. The second is endoscopic submucosal dissection (ESD), in which endoscopic tools are used to dissect lesions from the submucosa. Lesions larger than 2 cm are difficult to treat with EMR since piecemeal resection is often necessary, which requires a higher level of endoscopic expertise, increases the chances of complications, and often makes it impossible to be conclusive about the completeness of the resection at the lateral margins. The technique of ESD can remove larger lesions intact, but expertise in this technique in the esophagus is not widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204695537\">",
"    <span class=\"h3\">",
"     ER plus PDT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of PDT or argon plasma coagulation (APC) to ER may allow for treatment of larger lesions with a lower recurrence rate; furthermore, for patients with extensive areas of Barrett's mucosa, it permits treatment of the whole Barrett's segment in one session [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of this approach was shown in a retrospective report comparing outcomes of 24 patients treated with combined EMR plus PDT for superficial adenocarcinoma to those of 64 patients who underwent esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/66\">",
"     66",
"    </a>",
"    ]. More surgically treated patients had procedure-related complications (31 versus 4) and there was one postsurgical death (versus none after",
"    <span class=\"nowrap\">",
"     EMR/PDT).",
"    </span>",
"    There were no recurrences after esophagectomy (median follow-up 19 months) compared to four in the",
"    <span class=\"nowrap\">",
"     EMR/PDT",
"    </span>",
"    group (median follow-up 12 months). Of the four endoscopically treated patients who failed to respond to therapy, two were successfully treated by alternative means, and two died of other causes.",
"   </p>",
"   <p>",
"    However, as noted below, both PDT and APC have their drawbacks in terms of complications (primarily esophageal stenosis). A newer endoscopic ablative technique used to treat dysplastic Barrett's epithelium, balloon-based radiofrequency ablation (RFA) may overcome this drawback, but experience is limited using this technique to treat esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. PDT, APC and RFA are discussed in more detail below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of Barrett's esophagus\", section on 'Endoscopic ablative therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether ER should be considered an acceptable alternative to surgery for the treatment of superficial esophageal cancer is controversial, and the subject of ongoing debate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Although preservation of the esophagus is a major benefit, there is an absence of randomized trials comparing ER to esophagectomy and limited number of studies reporting long-term follow-up data after ER.",
"   </p>",
"   <p>",
"    Nevertheless, ER may be a reasonable option for selected patients with superficial cancers that are limited to the mucosa (T1a, (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 4",
"    </a>",
"    )), and who are willing to trade ease of treatment and esophageal preservation for some level of uncertainty as to long-term outcomes and the potential need for multiple repeat endoscopies, or for those who are poor candidates for surgical resection. The ideal candidate has a solitary, small (ie &lt; 2 cm diameter), flat-type mucosal lesion without evidence of lymphatic invasion (",
"    <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"     figure 1",
"    </a>",
"    ) within a short segment of Barrett's esophagus. Patients in whom a diagnostic endoscopic resection is not feasible because of poor lifting or an inability to suction the lesion into the endoscopic resection cap, both possible signs of submucosal growth, should be referred for surgery.",
"   </p>",
"   <p>",
"    ER is technically demanding, and should be performed only in specialized centers that have integrated expertise in gastrointestinal endoscopy, imaging, surgery, and histopathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specialized circumferential device for delivering radiofrequency energy to ablate Barrett's esophagus is available and has promising initial results in patients with dysplastic Barrett's epithelium (the Halo system). A potential role for RFA in conjunction with ER for the treatment of early intramucosal esophageal cancer arising in the setting of Barrett&rsquo;s esophagus has been suggested but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link&amp;anchor=H15#H15\">",
"     \"Radiofrequency ablation for Barrett's esophagus\", section on 'Combining endoscopic mucosal resection and RFA for high-grade dysplasia and intramucosal carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PDT relies upon a drug-light interaction to induce cell death. After injection of a photosensitizing agent and a suitable time interval, tumor tissue that has retained the photosensitizing agent is exposed to light of an appropriate wavelength, delivered through a fiber introduced through the endoscope. A nonthermal phototoxic reaction ensues, which leads to delayed cell death.",
"   </p>",
"   <p>",
"    PDT is approved for treatment of HGD in patients with Barrett's esophagus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with superficial esophageal cancer, long-term tumor control has been achieved in small numbers of patients treated with PDT with or without ER, but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/66,67,76-83\">",
"     66,67,76-83",
"    </a>",
"    ]. In one of the largest series of 31 patients with Barrett's esophagus and a superficial adenocarcinoma treated with PDT alone and followed for an average of 37 months, all achieved a complete response endoscopically, but there were ten tumor recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/76\">",
"     76",
"    </a>",
"    ]. Despite this, there were no deaths attributable to Barrett's neoplasia. Other reports are not as favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the advantages of PDT are that treatment is limited to the mucosa (and thus there is little risk of perforation), a broad area of Barrett's esophagus can be treated, and it can be performed in an outpatient setting. The main disadvantages are the lack of a pathologic specimen, the potential for inadequate treatment leading to recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/82\">",
"     82",
"    </a>",
"    ], the regrowth of squamous mucosa over intestinal metaplasia, which remains at risk for malignant transformation, and the frequent occurrence of strictures. Furthermore, PDT is expensive and is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uncertainties as to long-term outcomes make it difficult to precisely define the role of PDT in the management of patients with superficial esophageal cancer. We reserve PDT for patients with large early cancers in the setting of extensive Barrett's who are poor surgical candidates. Small tumors are better treated with ER. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laser ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lasers have been primarily used for palliation of advanced cancer, there has been a resurgence of interest in their use for superficial esophageal cancers and HGD. Three types of lasers are available which operate at different wavelengths; the depth of penetration is directly related to the wavelength:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neodynium:yttrium-aluminum-garnet (Nd:YAG) &mdash; 1064 nm, depth of penetration 4 mm",
"     </li>",
"     <li>",
"      Potassium titanyl phosphate &mdash; 532 nm, depth of penetration 1 mm",
"     </li>",
"     <li>",
"      Argon &mdash; 514.5 nm, depth of penetration 1 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only a few studies have evaluated the efficacy of lasers for superficial cancers in patients with Barrett's esophagus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early series, 33 patients were treated with a Nd:YAG laser, 27 for superficial esophageal cancer and 6 for superficial gastric cardia cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/85\">",
"       85",
"      </a>",
"      ]. Of the 22 who were followed for 24 to 55 months, six recurred.",
"     </li>",
"     <li>",
"      Two later studies totaling 20 patients with HGD or superficial cancer managed with a Nd:YAG laser reported only one recurrence after 36 months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. Complications in one of the studies (n = 14) included odynophagia, dysphagia, and chest pain in 4, 2, and 3 patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of laser therapy in the treatment of superficial esophageal cancer is uncertain. The use of lasers has largely been replaced by the other techniques discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Argon plasma coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An argon plasma coagulator is a non-contact electrocoagulation device that involves a high-frequency monopolar current which is conducted to the tissue by a flow of ionized argon gas. The depth of necrosis, which can reach up to 6 mm, varies according to the power setting of the generator, the distance of the probe tip from the mucosa, the amount of gas flow, and the duration of the application [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience with APC is limited in patients with superficial esophageal cancers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 10 patients, only three of whom had early adenocarcinoma (the rest HGD), eight had complete regression of their neoplastic process [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/89\">",
"       89",
"      </a>",
"      ]. One patient with HGD had persistent HGD while one other progressed to cancer.",
"     </li>",
"     <li>",
"      In a second series, one of three patients with intramucosal carcinoma recurred after APC and required retreatment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/90\">",
"       90",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the lack of a specimen for histologic review, other disadvantages of both laser and APC include inhomogeneous mucosal ablation, the need for repeated sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/85\">",
"     85",
"    </a>",
"    ], and possible persistence of metaplastic glands under the neosquamous epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/88\">",
"     88",
"    </a>",
"    ]. Although rare, perforation and death have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of APC in the treatment of superficial esophageal cancer is uncertain; further experience with this approach is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5737946\">",
"    <span class=\"h2\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic cryotherapy is a relatively new therapy for superficial esophageal cancer with very limited experience thus far. One report included 79 subjects with esophageal cancer for whom conventional therapy had failed, was refused, or considered not feasible (n = 60 T1, n = 16 T2, and n = 3 T3 or 4 disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/92\">",
"     92",
"    </a>",
"    ]. Endoscopic spray cryotherapy was performed with low-pressure liquid nitrogen, with each mucosal site frozen for 20 seconds, followed by a 45 second thaw for three cycles. Treatment was repeated every four to six weeks until complete local tumor eradication, tumor progression, patient preference, or a comorbid condition precluded further treatment.",
"   </p>",
"   <p>",
"    The median number of treatments was three (range 1 to 25). Of the 49 who completed treatment, 31 (69 percent) had a complete response in intraluminal disease, including 18 of 24 (75 percent) with disease that was limited to the mucosa. Benign stricture was noted in 10 patients (13 percent), of whom nine had narrowing from prior endoscopic therapies. However, follow-up was limited to less than one year in most patients.",
"   </p>",
"   <p>",
"    This technique is now available and is being selectively used for this indication. However, additional experience is needed to ascertain the appropriate place for cryotherapy in the treatment algorithm for superficial esophageal cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RADIATION WITH OR WITHOUT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the data are limited, external beam radiation therapy (EBRT) with or without concurrent chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraluminal brachytherapy are potentially useful alternatives to esophagectomy for patients with superficial invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/93-99\">",
"     93-99",
"    </a>",
"    ]. Concurrent definitive chemoradiotherapy is considered a standard approach for patients with muscle-invasive squamous cell cancer, but the adequacy of nonsurgical approaches for invasive adenocarcinomas is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, as with endoscopic therapies, none of these approaches eliminates the risk of a local recurrence, which is higher for patients with submucosal (T1b) as compared to mucosal tumors (T1a) (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 5",
"    </a>",
"    ). The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series, 104 patients with superficial esophageal cancer underwent EBRT alone or with concurrent chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/93\">",
"       93",
"      </a>",
"      ]. The one-, two-, and three-year survival rates for patients with mucosal cancer were 95, 90, and 90 percent, respectively; the corresponding rates for those with submucosal involvement were 90, 81, and 70 percent, respectively. Patients who received chemotherapy had a better survival than did those treated with RT alone, although the difference was not statistically significant.",
"     </li>",
"     <li>",
"      The utility of chemoradiotherapy was further explored in a retrospective Japanese series of 173 EUS-staged patients with T1b squamous cell esophageal cancer, of whom 102 were treated with radical esophagectomy and 71 had definitive chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/99\">",
"       99",
"      </a>",
"      ]. Chemoradiotherapy consisted of EBRT (at least 50 Gy) with concurrent FU and cisplatin-based chemotherapy. At a median follow-up of 65 months for surgically-treated patients and 42 months for those who received definitive chemoradiotherapy, the difference in overall survival was potentially clinically meaningful but not statistically significant (three-year survival 87 versus 78 percent for surgically and non-surgically treated patients, respectively). The frequency of positive nodes was high in this group of surgically staged patients with T1b squamous cell carcinoma. Recurrences were more frequent in the chemoradiotherapy group (20 of 71 versus 12 of 102 patients). Furthermore, although post-chemoradiotherapy local recurrences could be controlled by salvage esophagectomy, only 4 of 12 patients with lymph node recurrence were cured of their disease. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether brachytherapy adds benefit to EBRT alone is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/96,97,100\">",
"     96,97,100",
"    </a>",
"    ]. The benefit of intraluminal brachytherapy was evaluated in series of 59 consecutive patients with submucosal esophageal cancer who were treated with EBRT without chemotherapy, 36 of whom also received brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/60/20426/abstract/96\">",
"     96",
"    </a>",
"    ]. Eight of the 23 patients treated with EBRT alone recurred locoregionally, compared to 6 of 36 in the combined treatment group (35 versus 17 percent). Overall, deaths were more frequently observed in the EBRT alone group, but the difference in disease-specific death rates between the EBRT and intraluminal brachytherapy groups was not statistically significant (39 versus 14 percent). Since this is not a randomized trial, the true contribution of brachytherapy to outcomes is uncertain.",
"   </p>",
"   <p>",
"    A disadvantage of RT as a form of nonsurgical therapy is the need for prolonged treatment (typically about five weeks of daily treatment) as opposed to a single treatment for ER.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of RT and chemoradiotherapy in the treatment of superficial esophageal cancer remains uncertain. In our view, the patients who are best suited for this approach are those with liver disease and varices, in whom ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PDT are contraindicated. However, the severity of the liver disease may preclude even chemotherapy and RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of superficial esophageal cancer (ie, limited to the mucosa or submucosa, T1 [(",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 5",
"    </a>",
"    )]) is increasing globally. At least in the United States, this has been attributed, at least in part, to routine endoscopic surveillance for malignancy and high-grade dysplasia (HGD) in patients with Barrett's esophagus. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The two major treatment options for early esophageal cancer are surgical esophagectomy and endoscopic resection. The depth of tumor invasion into the wall of the esophagus is an important factor in selecting treatment. If the patient is a candidate for endoscopic therapy, we suggest a diagnostic (and potentially therapeutic) endoscopic resection (ER) to more accurately define the depth of invasion. The presence of submucosal invasion, or muscularis mucosa invasion (ie, M3 tumors) with lymphovascular invasion (",
"    <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"     figure 1",
"    </a>",
"    ) increases the risk for lymph node metastases, and these patients are not good candidates for endoscopic therapy alone. Furthermore, if a diagnostic ER is not feasible because of poor lifting or an inability to suction the lesion into the endoscopic resection cap, both possible signs of submucosal growth, patients should be referred for surgery. The contribution of endoscopic ultrasound for tumor staging and treatment decision-making is controversial. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Accuracy of EUS in the staging evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathologic subclassification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other factors to consider in the selection of endoscopic versus surgical treatment are the size of the lesion, the macroscopic endoscopic appearance (flat versus non-flat), the presence and extent of Barrett's mucosa, other esophageal pathology (particularly varices), comorbid medical conditions, the age of the patient, the availability of the various treatments in a particular center, and the desire of the patient for endoscopic therapy. Regardless of the approach chosen, patients with superficial esophageal cancer are best treated in high volume centers that specialize in treatment of esophageal cancer.",
"   </p>",
"   <p>",
"    The following represents our general approach to treating superficial esophageal cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For fit patients with submucosal (T1b) (",
"      <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"       table 5",
"      </a>",
"      ) cancer, we recommend esophagectomy over endoscopic resection (ER), which will maximize the chance for cure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Esophagectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with M1 and M2 tumors, as well as those with well-differentiated M3 disease without lymphatic invasion (",
"      <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"       figure 1",
"      </a>",
"      ), esophagectomy represents the most definitive approach, but endoscopic ER is a reasonable alternative. For patients with favorable mucosal tumors who are interested in an esophagus-sparing approach or are elderly, with multiple comorbidities, or otherwise high surgical risk, and who are treated at institutions with expertise in this technique, we suggest ER rather than surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Endoscopic mucosal resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For fit patients with long segment Barrett's extensive mucosal tumor disease, or M3 disease with lymphatic invasion, we suggest esophagectomy rather than endoscopic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For poorer-risk patients, PDT is an acceptable alternative approach, but outcomes may be inferior. ER may be used along with PDT or RFA therapy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Photodynamic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We reserve RT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemoradiotherapy for patients with superficial esophageal cancer who are ineligible for endoscopic therapy (eg, because of the presence of varices, previous perforation, severe cervical spine disease) and for those unwilling to travel to centers of excellence for treatment who can undergo RT close to home.",
"     </li>",
"     <li>",
"      The importance of prolonged follow-up in patients treated with an endoscopic approach cannot be overemphasized, as late recurrences may develop. These recurrences can usually be effectively treated if detected at an early stage.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/1\">",
"      Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/2\">",
"      Wang GQ, Jiao GG, Chang FB, et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. Ann Thorac Surg 2004; 77:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/3\">",
"      Kanamoto A, Yamaguchi H, Nakanishi Y, et al. Clinicopathological study of multiple superficial oesophageal carcinoma. Br J Surg 2000; 87:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/4\">",
"      Tachibana M, Hirahara N, Kinugasa S, Yoshimura H. Clinicopathologic features of superficial esophageal cancer: results of consecutive 100 patients. Ann Surg Oncol 2008; 15:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/5\">",
"      Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003; 98:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/6\">",
"      Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002; 37:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/7\">",
"      Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002; 11:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/8\">",
"      Endo M, Yoshino K, Kawano T, et al. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus 2000; 13:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/9\">",
"      Fujita H, Sueyoshi S, Yamana H, et al. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 2001; 25:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/10\">",
"      Liu L, Hofstetter WL, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 2005; 29:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/11\">",
"      Westerterp M, Koppert LB, Buskens CJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 2005; 446:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/12\">",
"      Rice TW, Blackstone EH, Goldblum JR, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001; 122:1077.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/14\">",
"      Barbour AP, Jones M, Brown I, et al. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2010; 17:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/15\">",
"      Shimada H, Nabeya Y, Matsubara H, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006; 191:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/16\">",
"      Araki K, Ohno S, Egashira A, et al. Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer 2002; 94:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/17\">",
"      Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol 2008; 15:3278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/18\">",
"      Sepesi B, Watson TJ, Zhou D, et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg 2010; 210:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/19\">",
"      H&ouml;lscher AH, Bollschweiler E, Schr&ouml;der W, et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 2011; 254:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/20\">",
"      Yanai H, Harada T, Okamoto T, et al. Prognostic value and interobserver agreement of endoscopic ultrasonography for superficial squamous cell carcinoma of the esophagus: a prospective study. Int J Gastrointest Cancer 2003; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/21\">",
"      Eguchi T, Nakanishi Y, Shimoda T, et al. Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol 2006; 19:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/22\">",
"      Shimizu Y, Tsukagoshi H, Fujita M, et al. Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc 2002; 56:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/23\">",
"      Ishihara R, Tanaka H, Iishi H, et al. Long-term outcome of esophageal mucosal squamous cell carcinoma without lymphovascular involvement after endoscopic resection. Cancer 2008; 112:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/24\">",
"      Nagawa H, Kaizaki S, Seto Y, et al. The relationship of macroscopic shape of superficial esophageal carcinoma to depth of invasion and regional lymph node metastasis. Cancer 1995; 75:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/25\">",
"      Cen P, Hofstetter WL, Correa AM, et al. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 2008; 112:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/26\">",
"      Badreddine RJ, Prasad GA, Lewis JT, et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol 2010; 8:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/27\">",
"      Young PE, Gentry AB, Acosta RD, et al. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 2010; 8:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/28\">",
"      Thosani N, Singh H, Kapadia A, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 2012; 75:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/29\">",
"      Pouw RE, Heldoorn N, Herrero LA, et al. Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases. Gastrointest Endosc 2011; 73:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/30\">",
"      Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/31\">",
"      Dimick JB, Wainess RM, Upchurch GR Jr, et al. National trends in outcomes for esophageal resection. Ann Thorac Surg 2005; 79:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/32\">",
"      Patti MG, Corvera CU, Glasgow RE, Way LW. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998; 2:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/33\">",
"      Metzger R, Bollschweiler E, Vallb&ouml;hmer D, et al. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus 2004; 17:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/34\">",
"      van Lanschot JJ, Hulscher JB, Buskens CJ, et al. Hospital volume and hospital mortality for esophagectomy. Cancer 2001; 91:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/35\">",
"      Kuo EY, Chang Y, Wright CD. Impact of hospital volume on clinical and economic outcomes for esophagectomy. Ann Thorac Surg 2001; 72:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/36\">",
"      Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/37\">",
"      Gordon TA, Bowman HM, Bass EB, et al. Complex gastrointestinal surgery: impact of provider experience on clinical and economic outcomes. J Am Coll Surg 1999; 189:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/38\">",
"      Gillison EW, Powell J, McConkey CC, Spychal RT. Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg 2002; 89:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/39\">",
"      Zaninotto G, Parenti AR, Ruol A, et al. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 2000; 87:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/40\">",
"      Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997; 114:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/41\">",
"      Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg 1996; 223:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/42\">",
"      Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996; 224:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/43\">",
"      Altorki NK, Lee PC, Liss Y, et al. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg 2008; 247:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/44\">",
"      Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg 2009; 87:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/45\">",
"      Tanaka T, Matono S, Nagano T, et al. Esophagectomy with extended lymphadenectomy for submucosal esophageal cancer: long-term outcomes and prognostic factors. Ann Surg Oncol 2012; 19:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/46\">",
"      Reed MF, Tolis G Jr, Edil BH, et al. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg 2005; 79:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/47\">",
"      Headrick JR, Nichols FC 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002; 73:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/48\">",
"      Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993; 88:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/49\">",
"      Korst RJ, Altorki NK. High grade dysplasia: surveillance, mucosal ablation, or resection? World J Surg 2003; 27:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/50\">",
"      Pera M, Trastek VF, Carpenter HA, et al. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992; 54:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/51\">",
"      Moraca RJ, Low DE. Outcomes and health-related quality of life after esophagectomy for high-grade dysplasia and intramucosal cancer. Arch Surg 2006; 141:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/52\">",
"      Viklund P, Wengstr&ouml;m Y, Rouvelas I, et al. Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer 2006; 42:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/53\">",
"      Reynolds JV, McLaughlin R, Moore J, et al. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg 2006; 93:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/54\">",
"      Gemmill EH, McCulloch P. Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg 2007; 94:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/55\">",
"      Peyre CG, DeMeester SR, Rizzetto C, et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 2007; 246:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/56\">",
"      Banki F, Mason RJ, DeMeester SR, et al. Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002; 236:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/57\">",
"      Stein HJ, Feith M, Mueller J, et al. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000; 232:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/58\">",
"      Altorjay A, Kiss J, Pa&aacute;l B, et al. The place of gastro-jejuno-duodenal interposition following limited esophageal resection. Eur J Cardiothorac Surg 2005; 28:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/59\">",
"      Stein HJ, Hutter J, Feith M, von Rahden BH. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg 2007; 19:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/60\">",
"      Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/61\">",
"      Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/62\">",
"      Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/63\">",
"      Das A, Singh V, Fleischer DE, Sharma VK. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol 2008; 103:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/64\">",
"      Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/65\">",
"      Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005; 61:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/66\">",
"      Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003; 1:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/67\">",
"      Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001; 54:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/68\">",
"      Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/69\">",
"      Bergman JJ. Radiofrequency energy ablation of Barrett's esophagus: the best is yet to come! Gastrointest Endosc 2007; 65:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/70\">",
"      Bergman JJ. Endoscopic resection for treatment of mucosal Barrett's cancer: time to swing the pendulum. Gastrointest Endosc 2007; 65:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/71\">",
"      DeMeester SR. EMR for intramucosal adenocarcinoma of the esophagus: does one size fit all? Gastrointest Endosc 2007; 65:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/72\">",
"      Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/73\">",
"      Pouw RE, Gondrie JJ, Curvers WL, et al. Successful balloon-based radiofrequency ablation of a widespread early squamous cell carcinoma and high-grade dysplasia of the esophagus: a case report. Gastrointest Endosc 2008; 68:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/74\">",
"      Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/75\">",
"      Bergman JJ, Zhang YM, He S, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc 2011; 74:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/76\">",
"      Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/77\">",
"      Nakamura T, Fukui H, Shirakawa K, et al. Photodynamic therapy of superficial esophageal cancer with a transparent hood. Gastrointest Endosc 2004; 60:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/78\">",
"      Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 2002; 77:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/79\">",
"      Tan WC, Fulljames C, Stone N, et al. Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasia. J Photochem Photobiol B 1999; 53:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/80\">",
"      Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/81\">",
"      Gossner L, May A, Sroka R, et al. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer 1999; 86:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/82\">",
"      Peters F, Kara M, Rosmolen W, et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in barrett esophagus after endoscopic resection. Endoscopy 2005; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/83\">",
"      Tanaka T, Matono S, Nagano T, et al. Photodynamic therapy for large superficial squamous cell carcinoma of the esophagus. Gastrointest Endosc 2011; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/84\">",
"      Keeley SB, Pennathur A, Gooding W, et al. Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol 2007; 14:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/85\">",
"      Yang GR, Zhao LQ, Li SS, et al. Endoscopic Nd:YAG laser therapy in patients with early superficial carcinoma of the esophagus and the gastric cardia. Endoscopy 1994; 26:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/86\">",
"      Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation of early Barrett's adenocarcinoma: long-term follow-up. Gastrointest Endosc 1999; 49:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/87\">",
"      Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002; 97:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/88\">",
"      Conio M, Cameron AJ, Chak A, et al. Endoscopic treatment of high-grade dysplasia and early cancer in Barrett's oesophagus. Lancet Oncol 2005; 6:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/89\">",
"      Van Laethem JL, Jagodzinski R, Peny MO, et al. Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma. Endoscopy 2001; 33:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/90\">",
"      May A, Gossner L, G&uuml;nter E, et al. Local treatment of early cancer in short Barrett's esophagus by means of argon plasma coagulation: initial experience. Endoscopy 1999; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/91\">",
"      Morris CD, Byrne JP, Armstrong GR, Attwood SE. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001; 88:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/92\">",
"      Greenwald BD, Dumot JA, Abrams JA, et al. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc 2010; 71:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/93\">",
"      Nemoto K, Yamada S, Nishio M, et al. Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Anticancer Res 2006; 26:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/94\">",
"      Maingon P, d'Hombres A, Truc G, et al. High dose rate brachytherapy for superficial cancer of the esophagus. Int J Radiat Oncol Biol Phys 2000; 46:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/95\">",
"      Okawa T, Tanaka M, Kita-Okawa M, et al. Superficial esophageal cancer: multicenter analysis of results of definitive radiation therapy in Japan. Radiology 1995; 196:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/96\">",
"      Ishikawa H, Nonaka T, Sakurai H, et al. Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results. Int J Radiat Oncol Biol Phys 2010; 76:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/97\">",
"      Pasquier D, Mirabel X, Adenis A, et al. External beam radiation therapy followed by high-dose-rate brachytherapy for inoperable superficial esophageal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/98\">",
"      Sasaki T, Nakamura K, Shioyama Y, et al. Treatment outcomes of radiotherapy for patients with stage I esophageal cancer: a single institute experience. Am J Clin Oncol 2007; 30:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/99\">",
"      Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol 2012; 19:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/60/20426/abstract/100\">",
"      Kodaira T, Fuwa N, Tachibana H, et al. Retrospective analysis of definitive radiotherapy for patients with superficial esophageal carcinoma: Consideration of the optimal treatment method with a focus on late morbidity. Radiother Oncol 2010; 95:234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2494 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20426=[""].join("\n");
var outline_f19_60_20426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathologic subclassification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Accuracy of EUS in the staging evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ESOPHAGECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The volume-performance relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Impact on health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Less radical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Minimally invasive esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vagal-sparing esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Limited esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ENDOSCOPIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endoscopic mucosal resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Endoscopic resection versus surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H204695537\">",
"      - ER plus PDT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laser ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Argon plasma coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5737946\">",
"      Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RADIATION WITH OR WITHOUT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2494|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/9/38035\" title=\"diagnostic image 1\">",
"      EUS five layer pattern",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2494|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17302\" title=\"figure 1\">",
"      Depth invasion esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/35/4668\" title=\"table 1\">",
"      T stage esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/7/13437\" title=\"table 2\">",
"      Incid LN mets superf esoph CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/60/13261\" title=\"table 3\">",
"      Esophagectomysuperf esoph CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13934\" title=\"table 4\">",
"      TNM staging esoph SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/24/4494\" title=\"table 5\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=related_link\">",
"      Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24597?source=related_link\">",
"      Endoscopic ultrasound: Anatomy of the normal esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=related_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=related_link\">",
"      Surgical oncologic principles for management of resectable esophageal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_60_20427="Insulin algorithm lispro";
var content_f19_60_20427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F83953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F83953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Insulin algorithm: Lispro insulin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Blood glucose values",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Change in dose, units of insulin lispro",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\">",
"        mmol/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        &lt;4.4",
"       </td>",
"       <td>",
"        - 2 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80 to 120",
"       </td>",
"       <td>",
"        4.4 to 6.7",
"       </td>",
"       <td>",
"        &plusmn; 0 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        121 to 140",
"       </td>",
"       <td>",
"        6.7 to 7.8",
"       </td>",
"       <td>",
"        + 1 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        141 to 160",
"       </td>",
"       <td>",
"        7.8 to 8.9",
"       </td>",
"       <td>",
"        + 2 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        161 to 200",
"       </td>",
"       <td>",
"        8.9 to 11.1",
"       </td>",
"       <td>",
"        + 3 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;200",
"       </td>",
"       <td>",
"        &gt;11.1",
"       </td>",
"       <td>",
"        + 4 units",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20427=[""].join("\n");
var outline_f19_60_20427=null;
var title_f19_60_20428="Evaluation bronchiectasis 1";
var content_f19_60_20428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of bronchiectasis-1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific examples/features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Acquired bronchial obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Foreign-body aspiration",
"       </td>",
"       <td>",
"        Peanut; chicken bone; tooth; grass inflorescence, etc",
"       </td>",
"       <td>",
"        Chest imaging; fiberoptic bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumors",
"       </td>",
"       <td>",
"        Laryngeal papillomatosis; airway adenoma; endobronchial teratoma",
"       </td>",
"       <td>",
"        Chest imaging; fiberoptic bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hilar adenopathy",
"       </td>",
"       <td>",
"        Tuberculosis; histoplasmosis; sarcoidosis",
"       </td>",
"       <td>",
"        PPD; chest imaging; fiberoptic bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        COPD",
"       </td>",
"       <td>",
"        Chronic bronchitis",
"       </td>",
"       <td>",
"        Pulmonary function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatic&nbsp;disease",
"       </td>",
"       <td>",
"        Relapsing polychondritis (RP); tracheobronchial amyloidosis",
"       </td>",
"       <td>",
"        Clinical syndrome of RP/cartilage biopsy; biopsy for amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucoid impaction",
"       </td>",
"       <td>",
"        Allergic bronchopulmonary aspergillosis; bronchocentric granulomatosis (BG); postoperative mucoid impaction",
"       </td>",
"       <td>",
"        Total and aspergillus specific IgE; specific aspergillus IgG; Aspergillus skin test; chest imaging; biopsy for BG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Congenital anatomic defects that may cause bronchial obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tracheobronchial",
"       </td>",
"       <td>",
"        Bronchomalacia; bronchial cyst; cartilage deficiency (Williams-Campbell syndrome); tracheobronchomegaly (Mounier-Kuhn syndrome); ectopic bronchus; tracheoesophageal fistula",
"       </td>",
"       <td>",
"        Chest CT imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vascular",
"       </td>",
"       <td>",
"        Pulmonary (intralobar) sequestration; pulmonary artery aneurysm",
"       </td>",
"       <td>",
"        Chest CT imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphatic",
"       </td>",
"       <td>",
"        Yellow-nail syndrome",
"       </td>",
"       <td>",
"        History of dystrophic, slow growing nails",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COPD: chronic obstructive pulmonary disease; RP: relapsing polychondritis; BG: bronchocentric granulomatosis; CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20428=[""].join("\n");
var outline_f19_60_20428=null;
var title_f19_60_20429="Early v late HCT in myeloma";
var content_f19_60_20429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival with early versus late autologous hematopoietic cell transplant in multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 318px; background-image: url(data:image/gif;base64,R0lGODlhoQE+AdUAAP///4CAgP+AgICZ/wAAAEBAQMDAwP8AAAAz///AwCAgIDAwMP9AQKCgoMDN//Dw8HBwcFBQUEBm/7CwsJCQkNDQ0ODg4BAQEH8Zf2BgYKCz/4BZv//w8P+goHCN/+Dm/xBA/yBN//9wcFBz//+wsP9gYP8gIP/g4NDZ//+QkP8QEP8wMGCA/59Tn79NgDBZ///Q0PDz/z8mv5Cm/4CJ7/9QULDA/3A8r7+MvwAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAChAT4BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsdiBhVDDw0BDQ9DEwEUFsjXvRUBBAVDC9wEC0IQ4RcX1tjptwUE3EITBBEAEQQTDwQXABQEEEIGAQADGFBHsJUBdwC2BUhIQKC7g90A/AsosKBFVBCFKGTosFtGIwABJBBAsqQAER0uqsz0cV8/chQqhAMATx7IhQlcYNjJcycN/w8aVgqNVGHfAgMPLBBQYEABAWtOJ9BrcCQkAAcDsmodQAPDDQRBh4pdxK4dgYENnCqgCqDCtwv9qi5U0uFAC7Bj84qyStcuXr2AOfHtezds4MOWBhNG4GGrVgeIIy9SrESECA2NHUsYILnzIcpJSCLJ6rn0INBIRB8hbbq1H9RHBDAomYAIa9e488A2MpLkbNuccwu3szu0AODDk88pnvr4kAGbs0JWTl0N89jOhWDNurm69zPXjcgWULvI7e/owYQvMvK3+eBaHEy/EsMBCiEoHMS4Kn/+h/79pSfMeuJl91x0W80nBQIILIGABEw48KAQEiAAGYMMghDUABhiKP9gMAQWoRoR223VHRUMEqGBBBKMYAMAGiAQwgAfwMjiDEVICCEAFV7Y4AcvWPjfDAi8IN+HwIRIxIhKnBdFikOM0FgICHzgAQIgSIDClR6MgACOQ0g44wBU+ihEjCNoNyGSSc41xXjkNQnfgg0O8QF0ZQKwJghjrqlmhxbqWaeOau7Ipi9KDtGbe6PN+WSdAHwAwgsasBDomjJqZdhVa/Yo6JkIsFDoob8kKqKBRjgJBYOPITCCA57K6MAHXg7ggAZzEsrjpRZqAAIINXJqKKm7mLokqu9VASgAlk4aKIcIoBADCyBgmWunvDI4wn2jEsuLsUMwmaqj3pY7BLhCwBn/p3kIDgCUueWiK1JJjIbp2JWbwoukvMc2EWO++qbHb7jIIvFvwPu6mYW6JpVXxMEIC6wwFr2ZNJ7BjDnmmIIRezawEuKqmJnG0JHbcWQfhzabxSQ53OjJpqWMRMUW17uayTAHJjMUISebc2c7P9Ezcj9LFrQTDNP2HM5Fj3V0EzTTm52qTef1NBUjUl21WFe/OXW7HG+tUtdSjFhiyWJzPTEcSZe0wQYsK532NWRHEbVJb8d98dyzNENNNAD4DU0SdWuh9dB8q/LAN+xcEA3jMyFReBYlk+xCwYmrcpA47BhQ0zz1SL52HmebiAHmmaOyeDgKZMDR6/5QVMDogQyA/8HKcbuceigPZHCBUws8sNFGsQc0OyIDwK23zbt/ss9C9FDDDwAwiY4804g3r0kD4RjwTQNKMeUUOjddr7Le6Les/SMQXLDUXGktxZZc5s+cPvrMr9/J5GFoXUX2+sME/8BQuQRZAYABTAztAFE6tP0PdQm8xADN4L8mIDCCk5hgGQq4MQvibl0YlOACDdFA7jCNCDTLXwgjocE2VLA5KxQhJl6InRi2oQEDockExtBCNtCwQDZkw/GoF5Ew9HANPxTRB/WmuyBe4SBmaYdNjDhCRyQRhffbmxOzUIEC/K4ABYjAMsRwRDVwkGS2KhsEtygFHIKnio0ooWZOmBrcNf+RjVF4AAUCMj/1wDETV1SU1PBohbK0o4h+LEUggUhIKnTPAMrg4R9n2C40Sic2S7xjI4+wgElmoYx2kKPGTsSemq1xk+NQAB8lSYsfXnCThkQIFVtJx3R9UJObrAAkITnGWc7ihyk8JRsfAIECVCACOySjJxVZS0aisgj0OEsGppjIXzbzVM80AgEoUIB/IPILoCTEGS05Hzjhko316GYYWTkLUc5RkFp8pu9+R4A+gnOZ1nTmMx9AD7iQIZySUNUrY2iBgTwAKewMhkCXmDsbLkAeD2hdQoGhqruxTIX6O4tGvukFgEZikekSZuouQAEhRICa9xzGODUWtoEmLgP/4fjeRH/hThPqE4O9w0dclHkRgYo0cxXo5T/x+YuFNnR9YHxjT8llUYzObQLiMINHO5FEl/4slhztwlQ5sdJLEkx/xQRjAXZazYKIkpQAsOrPDsrWmYrlPGqFGffOsgCyLsFvcxEc4OgHGLj+tGgKWABTApDVI1TAfQVQgBAgF1W+6gWudtzdWbpZTCc4pZefo0cyJSI7oiLjPBVzatNa10l/MkEmCnCKPIbXkCFMBCBDfCzO4howeLTjHE3YnPfqyVrabZWZMNydNqrhBJl0QyEuod42rdfXSmrlbR1M2zSIa9l6fMMA4WvKU5irF1FuoCcYkIHymBgxctxWqEpw/ws+2BK/tRDOsyqJWt6W91f0xMNzF0BpR+E7Fv/RljpH2ahbXePf+n6nmLCdnT258FtaGidisTykL4fT1eRtIGze0uUueTlh4bhzAzK4Zggb7AsBYEDEGCRxL0yM4giqmBcszuaLdxHjjhkgAznssIBM7Fw0Ypg6MuEGehnMX88IwAWWfCeS/rHgLcxYF6/k4I/n9uRctE1vOuFJiIcTRbMU1slF7oxFs8iAEw9HrGi2637FVuPmVVkdbRbOMcWqZq2G+UNxzs03vDxgmOUZN/UkAAAycOclvDkdJh6vxc6Zl7MwpbI83VoC5mvK0qgSpvHoM8yo9l91BJWfEdhrWf+rttIN4KA0CJVqoQUkR7RGhh0Z2GykmwdSizRgzwoo6ax3V+uLdFGWo05d8rJI3nTc+ra61nHmhk3sSqcD1rJWduJq3WlbpLoMhx5KhZMM3SR726uvCIAFnLHKXaeuppbs9rct6WpWTDaKX9ZCtodT7V53Aika5rC5G1nvFouCAtHeNyH7PQt2KAAC5JM2HgkuiwpAYM+uE/jCDewzWTSDHfH+5KozZ04q2NsT5r2vpre4KIoD4OOdKMACBhcFXaJDr+/NZr+mgHJORFIKh20tABgbc5mH1OP+DkVSpbDnhWQ2dI6VOW1rvgmoSiEAcGltb13bWZ//nOZBBwVWmyD/k2lI/etuei1hN767pWf9E2EFY51B0mXpvWS5Sc/m0nu8bgOyoqA3JkAGLJDd8XFX6SZH97qnHIm0jxUKxGtvkzVC9tRdudmQhzyjFbF1iTdyzJHP/P0m3wgFBNzOVr/IAjKOhXmHXhFh/YZ+QX/6axhSAUNmfeslNntjTKCbq1s7kWtfjAyII+SLBzPviXG8b1jgpCMffi7Geg/FEjb5+kuA9KXfBBEwYAkcSAAMhACDBHAAAN2X/vcBkP3pi98TRtH7PFa/eyce4P3vbwIDDrCEBBzg+gCYf23mD38RiAT+8Md5kbA656AUyRZsK/R+0wcAJ1ACDMAAIvB9HSAA/yeQAicwfwBAAhQIABM4fv+Hf/qXfwfgfSVwAAJQfgrofZ/QVgUlainlfiYoACmRALNRgiUggiowghhYFykAACpgAih0ACZAEiYwgiJYGydwACowBPGXDqYXGQCIfx3ggPcnguOHgRygAitAAgfQg4oCgAp4hELQhABAhnTTeDBjhiJwACJgf9eHgUIAhyW4AgfggR8Yh0YYgkkIhGNIf06IhifzfiUhgiRQF2/ohyIoBPZ3ADXAHlUohvOXAiRAhyTAhIh4hlsEhuCXg/N3iEMAhwBQhJUYhCCYh/C3hURghsjwhB/CAUIoHKwoIClggrAIiMpXELF4i6eQi7pYCv+82Iuj8IvAGArCOIyfUIzGuD+2mIzGgIzMqAnO+IwCtIzSOCDUWI1tgo2lEY3amEHX2I3f8o3gqAvcOI6PUI7m2AjomI52YAF7RAGAA3N/x47BYEhRxXPzSI+/YA8RdRZHt1liF1v6OAzjM3XFA1viOJDOMz0GWT4KGQzkEHHJVT1x95C7QA+qJBB9t10VaZG50HYAoHg955Fjk5AkyQrreJKAkJIq+Rom2ZKowJIwuQcyOZO68ZI2SQo1mZPEgZM8SYw++ZPHGJRCqYxFeQw7eZRwkJRK6QZM2ZRs8JRQaR1EOZUKZJUgUpVY6Y1bWSpa2ZWQIJVgCX1jCQtiWZb/CIiWtHCWail7bVkLbPmW8vaVcvkZdFmXhRCXeGkFermXVNCXfvl0dxmYKzmYhOmShxluhpmYNLmYjHmTj9kJ8piPkWkJ+EiZlTkJ/1gErwVGFPGZoBmaojmapFmapnmaqJmaqrmarNmarvmasBmbsvmaORaWYMeZxjM7s7mbo+mZvPmbsqObwDmchCWcxMmbvnmcvymQ53ibmFkHT/ZmVSadjukFEwl3HdmTfECdfcCdkrCRCceZtQmZjYmY21mdz7kIIokI0Yme2Qmd7umQngFJfECffWCfe4Cf+Tmemdmf/vmfALo1k0kH7vg3QjCgcOByB+oMLDcHeLWgz+CC/2/gN/AIoQ0KBzcXOAy6V9MVnpJwmXRgj4sFDo2VoO4zFyBqotygWDtHog4KOY7TouxQom2gDbKEj+SwAObgoY+wmXXAj07hOZmmWXJQdDQxpEgXB5clDUj6eWuwOQDQOT7qBmUREf94D/mQXJTQkHZQkM75BlBHDgvBpW6AWqr1OsQDB6sjWK5DpmzwEb2VER+RQV9aB8nlpmrQdVOXpm+gW9+Dp2vQO/QUPICaBnAKdnIKbJFwnQc4BxEpBIy6lG0XqXFgXBxBqXDwPKDjdsrVqG+KEIwqE+LwOZQAnnaAkQCBXUuhXTyaBngHU3tnqnIQFdclq3DAPUfxPbZao/9GgRSmGhVTYQnrWQcgOaxxkHhqEXxroF4XwF7JSgft8z5CYKxtEEto8axt8Ra6F6Dc2q3e+q3gGq7iOq7kWq7meq7omq7quq55AUmAo6A4VwDKyq5t0A4lpRQ61wTbMBAHEZ/q2g6KZV5zwU3IpBENwE0ZkBSwhkP8gGBCUAEZEEbzSq9hsBT1QE8LQQ4QQKTtIFh6VwHAAwFQ5EX1pBSdNE0UuwbcEAHmsBEXIA73IA/ucA/HpVH9eqQBgFoQUKEpmwbcAA8QsBEI4Q5DW7P82lo3e3vuQ6M9SwYPITytpVnbUFJFyxGQhLQNcWMTYADm0LRoIEsbwU86JQRVawE2qnWz/WoBe7YAsee1bvu2cBu3cju3dFu3dnu3eJu3eru3fNu3fvu3gBu4gju4hFu4hnu4PxkEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival results from a controlled trial in which 185 patients under the age of 57 were treated with three to four courses of vincristine, doxorubicin, and methylprednisolone; they were then randomly assigned to high-dose chemotherapy (HDT) and peripheral blood progenitor cell autotransplantation or to conventional chemotherapy with high-dose chemotherapy and autotransplantation performed as rescue treatment for primary resistance or relapse. Overall survival was equivalent in the two groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fermand, JP, Ravaud, P, Chevret, S, et al, Blood 1998; 92:3131.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20429=[""].join("\n");
var outline_f19_60_20429=null;
var title_f19_60_20430="Algorithm for evaluating children for disorders of hemostasis";
var content_f19_60_20430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluating children for disorders of hemostasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 362px; background-image: url(data:image/gif;base64,R0lGODlhzQFqAcQAAP///wAAAIiIiLu7u0RERCIiIpmZmd3d3WZmZhERETMzM+7u7szMzFVVVXd3d6qqqh8fHz8/P7+/v8/Pz09PT5+fn29vb6+vr9/f3+/v7w8PDwAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADNAWoBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgVQBhIWGh4iJiouMjY6PkJGSk5SMgpdzAZhvmpuebJ2faqGipWSkpmWoqaxcq61gr7Czg7Rjsra5Tbg7A7xZBwkGQAIEPAcFDya/us1GqAsNhQ45vifFIthVCNQAhQUDBYcCM9oovoQKyI0DAwkLJczO80GoCgrwAwrVr+ZWBwHgeRsmIIEIazX8mfB1AACBBgdJ+VMwjIQ8ehh5kGIQsISAdAwAICg0LFwhkcYA/xQwYM1AIQQACSHA5i6AMIcKZJJYQICQQZMBBBT7eEBaAHwAjOLzlTNByBEG9okIMIxjQ4QkYh5dwNRmyI+EUorQujRAQwEFIpLw5wCixYxwi5AKV4JjSARiRe5LQM0aXhErsQJwuUAbtgTkDLwjYIzhCF8CASAegXYAAAFIFQjNLMCXZQII1oaeOgxBWgCCSwB84NkhAo6WFY4NwNrsAgWjBfszkNdb3N/1SFglYeA03YKECgC8qumvSpaaohY6YJjA8qkHCJC7PsKBTQHcL6cc+ZK8TIQIRmdT/+1pagAMehKCLiJ98Wx545NEt1Ut5by8xQPcgD3Yow5qCtiVlP91tAHgQFqTfXRZWu7QVwA1D5iFGX6SkVMQT9uZZYJVk3F4GVLZoIhaJ+kRJ9VAJbyHwD4LUIXeawGE1EBeMwJQI3QNkaBbXm0JSOCROKCSnU/UgJWgQ8ml5VIA4gCwjgLCWAOWOAcwkEAAMzX25U3aWSliRDrVFJQ5RlGV1H4sqmemQG4KuUpN4tAnUmjkKZAXnjae+ZhEeVFkJJKIznBRC2ixwQ0Y7kQ2VaKUxrBoCmAlYNkawVTEBTLKHFrpqCpcSqpGp6Z6gqmqJtnqq77BKpesqrJKqwy23upMrrq6wGuvtvwKbKnDUlrJscgmq+yyzDYrbLHQQvFstNRWOm3/tdgeeW223Ma1bbfgzvNtuOQGW+65qY6L7rqiqMvuu5e4C++8fshL770tOKvvvvz2qwi+6UZrL8CfDLwrwaQa3IzCCAvCcC4PN/xHxLRQLDEfFsOS8cV5bMyKxxzLMQEFEvgmAQUT0DpyyZqcnHLIGUEQgMw060rzzDPDDFcFh1SgK8+G+KwzRhloUIgGGeha9NFJD42RBYVYACzUhEjtNEYYFIIBsFkTsvXVGEUQQATFik022BhdEMAFxarNNtphR3s23HTXbffdeHfhr7OY7A1J3l6AzILgVoBMOOC+ZnF4LUwsjvgKjq/a9y6PbxH5MpM3XrkWl4sKiOGbKz74/6ZCKNT5Ew+ndnrok5ZQ42nekB6E6ZmPQEhILvWCyuqsr4KZplPJTkxvvGtuUQFSbqs661esUoAALXqTk5sETB/aAdM3qZ1ZVMqUzmAvief5xPEUJEDu2BPSVwC+uCQOmN+TxdXuzBceY0CReuOhQYytWBREXhpAZaZCDtMcACCkIwzt4hUPA3xEQg0AoKZ8QQ79iUQ5CBzBapZXP8aNwDxuYp//yrSclYiAAA4Uiwi1wT7pEII6xKsdaRbwvuecUE+xE1/s9DMfDnZQCqRYQAJCtSERPsghIfoffNhnjhWmhH0XAkCGYDi+ejUQfJqI4BLbEQonBq9HP/LhD6VFHP+DzIYjyflMEtMXAO3ZLjZPFGByNBRDBlqkIlVi4/reqEP2AQqHrRsjGbFQvCWATpCDbJ4Mk1DIyhWvkYykHCJRJzo7GnKSlCTkIpEAScQ9cpNH6CTgPmlJJYgyb6R0mCQx2Ti/LatvrmwEK9dwSjzUcpbBgdYtcfmDXdbBl7xElS6DacVhEhNjAjsmMo2pzI4ls5nO7NXKTIYyaP5yWDermTXpAEw4AK0QQtumHLr5hqURAmnizESxqBYAq6UzDuR8Q9cC8LV3wiGebzCbPccJLbftE55y+ydABUrQQBb0n/i0SCwXytCGHtSgaEgoKB4aq1EUS6LhwmhFe6XRbmn/tKMRpehHLyrSiSYBN2jYkA9Amq2RyqBIAFCAWzQzJSpV0EW72JQIR4eCMhWopLScwQMMIkSi5ug+lynRCJKRU0sJbwQPgN0OWIotl64AAW4hgANqxIAHNCBBQx0M7FQ6G4F453Z6nFA6pqcMoHhqRTkpQEjeJ1fzZFAp82sKA8zDQzNy9acPtaoIpiRVhgynAQJwQGITCxGkrkhIsGuQCLQYQLQcMCgokcwwwjooHbkFMNTYKRM50xrQ5BAyJQAHYA8qWBVoxwGjEcBXu/pVZTiWrKgZqzgQQMOKoJCFcNTKCweVjQIswDyhEe0AQIiAG+XQQd9Z6lNvQNVqtTYF/4oBHnwSQNQvwQOpBXkrQCSlWcoyMY7iu8lCOoEbwsQ0uaEabWScK1kRDOevwmStSVtQgLwkYKZSqakJU6sMIaZjAWkFrviAUthCqIONBeDTC0XYJj21iDw1HU1UVwpUiyIhKkB4jxB8mt+CXpcIKPWBiInxohIT9MSyqi61YAwrGT/TwyntzVjEcVPLdTgN8uBPAHRcAhKzADaAaW4ak+ON4ZpANg5qzJ06Z2NmArkFjmmBkVmAlgU4QCoIwcpOn0xkxMbixyFlQZZVkpyvFAIsNhrTMLRDAKk6hAAJCFKYuyg8ODfmfQaoKfqm1wBrsDE0aBEHUowijHecaLUm3v/vYJk8qEKQ7kJIPmEFJ6MYnhzoft14rKifa18v3iSsZbLGjojbgOs5xbJCdKByljqMAU8VzWcI8pmO+xLHItFMQTLLlkXgpxz5R8yyAy+DDJEdcljD1s82RAoBY4Do4WfDkH6xpFOQZffiJtMO6UaEFtNjERzxiKJGtnCMvWr1avqxq1ZLq9eSkpVYdgRC1AyHA7vtc5wJwoguBAOmxBI5/9pOT4kwOsDB5OmQoE9/ZnKqNcHGQlN8enSkNpRsYm5HZ1ugNE7FsHNQZZIGNRcZIq8OSj6skLeK5cByea1wbQZbrRhTRO7pkBs33RdAOXH8PvkK+KMOEf8cylseqsr/86XTno/u5iv4eb5orgosi+ghRs850sstdcg5/QVjLkfOpx50HKvAMZWJzku0AhPrLRjQgp7NfJ4H7ET3h9F2FaF8CJBXr2QF41wczJcwu/f5tc/PuZ0PEuusGEKUG+Yc3TZh7XSA2yiZOAHRxryDwYDDbJZ/XK93EmEtjHsHL3hdvk1n9C6nePtRE1qljHFVT8EtpvfzOGlI7CVX9iur2cHzGwzGqchmkhRDuMIOPWBGX+9qy0m50YOec2kdPGvoY8h7je3lxYof5Df7IDkhwFNsR/VTWD1Ij43iFFU67/9olgS7d79rLpPx55jeG/EV4OyfN/3JAvD1JNBqqcd//52gIO32VlvWfuTXe2k2dIKiJXPUJV/SdtNBE3SFRZ6iDeiQE8RnQvJhEOSRQYXXf/ChaAAoH3K1cXyHFRCXeFRycCg4fhAFcv1GK5CnKzIXMAyYayanX0IXeTtYczYwck6VA13HdJnkg2bHbYZAZwe3Xr7yVNXBKMZAhDzlBDd4Kzm4ZiNghWAnhWOHAkd4hasUaT/IhOiHDdWjE0NBFZpgd0hReLHjHA/xEhboeGtRCFUoADzhE6hhcHSmHID3JlvhGUHxgUCQhTYoeZSGJoQgQFX4f52nWlqiHLGWevrGPsuxHFOoVCOAZGq4epHBaYtxIK4nQKSFWaiVS0roe/8OmIZ7SBoa+IbNF33JpUawpUPHJyhQcRqhCF2IwR3Jp3FzaAjbB4zldmtBWHW/B4u/tn4poSXNN4DkIELh4BSPll7JaICxWGrBsD8g4n9bhBnzhQrDsW+t2IBnJyhq+GY6JI0aJ4c75Sf2NYE0MXg91oLawR+hURNkUkEMYIKWUWF7phO9VH63MAVC9HXXtIzmJwVf9jkIKQaKyDkTGQYVWUnpyIOmxJA4JxceeZAOmZAsoG/18Vk0EHYwMIYkF3hTyIpmuIRieBpCFCo1oJI+F4ZTRTosSXIXeWYsUCOWoRgiQRLQdTtAAT3NFzsZtiLtAxXhgxZfUhZ6RX9HERL/VBFhdRYW4pBnxZeCr8d2d+gmZ2VsN/mTX4AKkxeA1GBkPVJfSuUcJjRmhFF7J6BA+7d6n4Ejd2EMAZBVxuASlkF3SxVaLpkSnidFBlFfNpCRr5KDinkdyPGCaAEm55hZNtRCw/ceLlR/oHEjSEUXOzVxmsZrOgGA1eF9lclbjYmWgfMCCUCPq+EgUtVoN9UoFRI76mcW77GbVNQpN8KNz0WaSORtt6glUpGYJuBuiuKaevMC3uFbUWJghYiPV3ITTBSB77ElGlIIEOFcToKVm0Kc2gFwsWMNXgImY2lcg6cizTmSFNmDMemKQLiRQthyzukK8qltZ6iF+elj+Amf/xi5nzRISw11oAjKL/9JUZjkmAxqLA9qTw4aoUgyoRRKIBZ6ocCRoRrqLR1qTRz6oRgRoiIqLiWqTCR6orqQoipqLi3KSyz6ohojo7gUozSaCjZ6o6WQozpaMD06STz6o6AkpKETpEQaCEZ6pOSjpKiToE76pFAapVJ6oNaFKEk6oDNmpQ1zpaakpQjDpZFUoVtapWL6pWSqLWOapWVKMGDKSV7KpmeKoWl6Y3JqpmqKpnZKpwPSps85LNPUMtWUEX8KAC4DL4NaqDaDM9oEF9mUM/PSqBAALN9ECOGUEZMaAJXKLpeaqbJiTgGATnHhqaAKL6LaNL3CTu4UF6iKL/+rOizzVE9x8ar4IqtlMzZHok8Ag6ttszZH4k8A46vQMjcEIqz4QqxMeqzISqRTui/SsqwOFQvOGq39EgUYdTgwd0t8CgOLU62JxE1YuqZY2J9dagfYmijbKq5h2pBpaa7Uiq5uSq7fiqdJWDo6KQMLFK5Q0JMvsGXlugdeqChPda7w92YgtHNi1wP3WobX4J01pQj1KoYPCwP8Gq+OqA6IIDwceEKYhUDCFWop8A1AsQjJ6AL/iisB267w149miZMrGbE5WUXpOpNWQphGxrIvywMTC5SU5xBuAWXuYJJbeVkDcB36gJKrQhBmJBhQp2Uj25gn263z936kZjvTM2f/xSCI6rNgBgeH8NAmHtJmVmmwC4ivUMmGp9F+NRuwVbt4WNtGWmsTc+Z2hIhZW6Ij7vgWOjsoZ+GLRIZVSAUajMGxZ8IRkkJXWFkVIqK0vlMAU2l4VBGevwa5R6F4IWslbsdGOCmwXRgaLhFsAbs/uZcUEgSJHSJ4hWGJpeeV2uElIdEWoFhHZFsCeLldvtVjmQu61dMQlKUph5EYiyFl1KG6AsC6DoJYs5az63o/lZdislGTC+kaFKSJgsKyUeQmpuEf2Ct7C0BDq0cOCvIXq2tsf0G3ELJHm+cUp4g5UCsfdTK1p8cQPjVgv8UgwdaBzqdpDbsSfAuz7woVwwdn/+qRtstgGfBbQfKbQsL4fcsRPdqRvwz8eBS7IgdmIpgXPqZlFEM7uB0hAqYJJk1GJe4xF76TEp/ZCaGZFg1sHGkhQsVBtJrwPnNXEZmLsps7wDZ8RD5lXqQ7boUxjXlJvKWmI7CrsL7ZKEVmuwFrGThcQTrcu0kVjpz4w9hYXNtLmGP7msrrETq2e5BhWjGRwVeRYpMGDyjVvtm7ncYAnAXIbnsonCwMIV+bFK33f087r1FrEQGbRgeXYGICtzq0EreRHF+rEy2It7FrlVxixPCHxMugxz7Fx3/oxyRkG9NDdwAcyAlgxTMIoDtLb6phlipRDKMxEhl8txpUycn1Vv+jtsrZ4J2jBrllIrlDmTzdY7nTEZCTW8eHrK0hOQO9ZSlQqxG9LAO/rK0RXAb6aq92BnR2zMsrFRa4Esw7+cxiC3bHTAbJ7AKZMsyGvMvM6M33dM0eKs0PCc6cIM5woblfIGLWegvcvMkW+abmrFBUErKK8M4ywM7kvI7pgHw2K8zRnLd12sxHm1TZm801oM8E/Yo8S8FE8M8fi84Zoc5LBbZuMhxD8mTI0x8jyD5u+D59YiYHptDz7G9769DFpWjwII/FgRfvs5VeabjuS3bJC64Km1qhVRrGQSgaXXmlN3uaYZeYZUAZNBu1wXslfQIMYXkoPSE+LWvbm4mACT7/g9lj1YvP2CqtWs03wdzByQW2qywb2rAStqhuwMVDgYLUN/17E6xDnvwctjicztYJ2uHVMz047AoxJmCcMGInb/3W9paXZh1HYJTW6pvU64V+TT3WUM29ci1qDdwRZYzVee2if5ccqXw/fy1/HhgWwXd6wPVHJL3WDL3ZJtLZQwYPoznXmmaeEI0C2WrNei2T46qu8lox7hpKdxDbzIzbtB2z6iTPs8CtC33Owj2jv92/3nrcrUDciJ3c6byiuf0Mu13Zvk2fxmPbA10xW50szdrd/mLdBPobvK2RVranc3reG5re4z3OcHqn240v5S0E800seare5M3eAXrb8h2n/+h93+0d3QC+3/F9L/WdiMw9Lwe+A4caqBjR4C/DLhDeK5D6GxX+qIrqqD/TM7+xqfTi4b1Sqr8h4vNC4qcaNQPSqvSi4r1Cq7/h4vMC472iq8BB4/Ri470CrMCh4/TC48BirL8B5PMi5Mla5EZOoeC9N5CT5EzuSkve5FDO5ClZ3fYdc5BzMblyrVdO4Gr93gGt3Yddn7CN5VMOr1Uu5l0OMFlO5RHN5WHu5cA8BCvWEy5LXVtu5WcO58Y8sJbGwWP2PPLhQAap2SagdDP92nHe5g6oh90hFooBFkr2gg5nAoH+IWaiytngaAAh6B48IjsVYZC+cDK7fN5Ak5kcU//kUCOpniMM/Glv/up3+Q1z/YJh2wCKXWNlXsMm0H6o5VM/l3XKneZKzYveeEJuNGr/nMMQoQAeWwJaxOxNrb0R+Y64oMh0Rwi29YJFMlQQEVYt8lVLB89XjF2+OBkI8SAhkR34XOC9fcckYOhY9W5ufRAwbMtgohWCSYiLOZAjPbnYCGdItoriPvB6ewL6BhBfEY18lgI+JUTVowIO/yJdxxheSe2YAjvX3j9+khZhpVgGUSTpMSPhTvDycFv7gBBDhN80rbHQTAJD9LwHpxDmnkWu1nlxdH/yheqlhSOkc2FyslFdvpaOGHYb8pLq1lO3yZgLa5Nd5wuhNouYMg7/+jNEz3MaTpEgWF9A2H7nY04CgEYcsGN9nUDsOJjrJ/Tz3dEAjuXreeHCxTcfwGVtxfgSoFlYeUbsv6Brt+7nAVkRUH96SD8WCVBnIx8MhB/tI1BsT/H314Dx1Vhta3K2BeEgHwEPM6IYMgjr3UzulHHyncCcaC7buu7pJhnzvREhNP/WTDRrqKciwRl21WO0QK/5WXwCX+VxjL9TnnhwKJVi8Zb4ocG8KfH75pYW6Pb34DYhS/X4XnK6md7tsVkfiOaVyT/7/Av2mV4SnfAglqHuZf+eo28CGbtxnC4nU5IT9l5/eueHFAYn0h+2IZEhuizsiY0CGRJb59FwL9T8/3wOAoZQLMARGEAyAC0wlqcYBIjKukPAtAUi0BC6QOFFcLVGroIAgHIpAYxAcxFwtBC2V4EhOCKd4XFgbDbQiKlhEYBIIw7mOb1uv+Pz+j0fX+6LAQoO8n2Z/dEhEvI5NOk9gOVBDirgLOJVktkpXnZ6foKG5nHqkYqe1h0kPBxuor7Cxpa6ytba3nqa+uHyatbp9gYL3wG3FA8jJ4ceJyrfHjM7S9tCT1tfD0a3YqNW8+rUgRu6BFh+EjiGAWmDenO/w2/3sceP0l6uBzTYgdOJH6FzYu7XQDoBw1hhMQ7JQVHu6iwgQCNBOj396mHkQw/JxozNfnlScoBJuGL/OP8WvNTQxRRhD+k4UNDCQCSPNh0K6ngzzMs5EgMQWKBDR4okbRr8QBfgQAMaCoSWYcDkhFOoRgAELLdAQYOhKAYUoJGinA4FARLwQNKURpN1XcLWMASWbUC3PAKYfTKXCskFq+b0NBNTTg64KQjktWEgAVtwi9nujBxoXprKli9jzqx5M+fOnu/RgbFVgI6KXKQkEFFA4VMACkjvWI3kxIOTWR+8BlC6RWoADxIIHIp1i1E56BigBeCg6x9DFF0cT77cSdsiz2cWMdBGHuAwhpEsQMBYQYrev7Hum8KAAJYW4NhLjq8z/itmWpIIIZXPxrg3cHQk0N56aRhgWxNnyaT/2x9UpXHCAP3c50KE6KCRxmrNEXACYVgJUCENRZQDgHYauuDXAOR9lGIeaExR2QEHfWUWAQyAcyJQadGX0Xw54mSHaExcBMV2V73QmnvlPIeATFYUWIYhWRmgwBEX9UbOg39EaNQCCzCBHI79OJdOdDgKJKJ1FQmgAHAqckdHA44s5ldRLQT0wFIuIBUkUjzqyKcy0fwUVJBGIbHQWl9FlYAQjIXV5FVZDbCVAnYW9mFwWBIHwFZnkbQfmFMyRkVdcJSpnW6hVkEFSKv6CJdsexXxk6o/dfHeh2T6yc2OuXayK6+3DJBACWz6opJpv8qHbDC+KhuLAu0Ry5MnKzUb/xmz1e5xLbbLgratt919G4u24VLTLbnkjntuseoiMWgygdXiLruypDuvMXiQ2MtB1HYi7xj+LmPuGUOGSMhJ9tKLcDv43qnvsaAA3G694EY7hqkQT6wwxRovEk2+AJCk4QjjLYBGFjY4kAaZrt6VlwEe0tSWyusowIN/esFVBgJgFOCoh/wVENZTroorsMUED4DAPlg5cEBiRgCx4V5OHpEyDQw4HYSIpD6m6lpGcnxv2B2HUeGQH4e81I8dYuoEK3QUgIWqSuwrwBQ4qOdGTUqqgAU4O/fgqAtoLDDCAXJG/MlL3w2OtA4HTMGUDap4IRsSz50UwNsA7En54AFEBP9tmiXkNvZkpgPiccMgNyEyGAQgYLIbQNcwrKY32xCiqXVfbKZ7RQgQagEk/s2zz3mpbXziuRhdNtIcOmBDzigs1ALxVHNR+/QvI3+AjTPeXAPqGbOr+oawv5C8Cak97nSmVW5Neu4s7N7ecQXn3UCGmit3ZvqnBctRcfON+kDWJNvVp3lI6F2pErACzmWqeryRGZF4Y4A9LQELdtoQUkaHOnJ8MCcMSwMBhmCWA+RjaRJJgAIQ4JequCBrRJif7yoUs/RdjWY8oFV2PlSGkeCFfU7yIQqNt6khnQJeZasMEHBQADDIsIALdArVXoiXBUQRhUSkFQ8ONaewkU9d15L/IDaiUA8lhlAyYTzXGGtijXU8ECNoTONO1oguOiJjjnj0iB3D1cc9bqxNgLTWIHdRSFzoMR4SAcPy4qWLRZbrkKwqCWEAZ7A/qlGB0BHLT77oAgdEYjFj0N9MkiOI35SALMDgFyrkhcoy8SQl2ZDkJP3RMEvSMluahI4jWCmFhsEHIVP5yyCq10hZyIuMsMDktqLxuCxM6TuI0drPoIYCJwXtimNLJIfo9LAW5OYEuHJPAoJpBhli4QtRsx6BVGmWLjhBOzs7kMtOdZY15MwETxuB0BA4NX0GgUFoYMFagBOir0HFLMnJx90UhEBmYosTZpNYZY5gHuAQID07+Fzh/16FzcPBT2OLE0sY6hYamSiTTqBzU3pWMIKBjEOVXdyHPrxJndM8J04BUhAE11c5kH4Rc2XoHFpiOgDDWcmDrxEO7Bp6stlJK5eCNMMz9cYgGrzIESiIUoPGcbCebXOXNu3mHKwgFU+64DcZhVtRCCACNxJJlYQqGKTMlK+l3Akc2xsHWNkpB71W5q3GSFqmyhG+/JyMgcH6mNikGlV+3NKiX6zTUga4Qa9iz4BhraVBeukIUoahAWoqwXWslxpVFKW0nNPoUeFq1H60EJZ1NdVzgucXCmIwCca7HG4jCIZyIHWwHjzSyZxKJ66sy7GNpSQ0dUM0WcmMCAX8Klrtlf/ITnbyBmOwkw2Qg8C1iggt3p1NXtLp2t9eySlyoOuB6FeEYN1za9IFKFb5+sUKmYW+BQzRTwxKUAJBiD8qI2BBIFqtcfkyl9w0wyTq0Ig7PPgaZqyHMg3cLAR/U8FiVRccZXkNVWyOI8p97Ih7VLESW8PCylIxIBeMYpe8+HQx7tWGucHKIXj4ji/WyXRcs7TXeIgkUtVjQpagTlha5BgTUsCGGPKw3JAxwchi8a90ch6/AMesFwtehvGYSAzqwHYFA8V9RItAJ5shjhyjMq+ioTQ6OcCsDxAtA87TuzQNWayvfDM6bgZEItwFLv6RiTiyCbbZKenMnEtDdLvgHyb/RJMujW4ZSWXYgL4QU44xlqilcrCUyHFOAI0Y9T56d8zxdYtxLliFibo55h7IrQkIGJ6DCg1UJPgnxMXhkJeUQ1OFWFRMdpMOTavDuVBmB4nxYHOutIGO6CWBznOelO+SkCBacnM5F6treEgVotdmtq9ZII8pJbQFClUGRMD+GLotVKoiiNtEKOLjplfkQLw5UFOMKcGWQ3pIbk6hdLeJn2toCG4iiRuqwWvy2nptpauUdkwo8R1orb0meu9YD0+83I8TFOTqDnLBJ7Spf2TogzId3L643sIIcLSpBHTK28C2p6iiKz7dFcHSmlKVTZjtJ5+H0MUaC5ail13vGSuuf8Yce1Ydj450GnP26X9yutQJIfSqFy3jWLe60re+TKp7XSNdD3sSwU52e0T97M8wu9o1CXSvvz1Hnpk73etu97vjPe9434Te++73vwM+8ILfTNsLb/jDIz7xil884xvv+MdDPvKSnzzlK2/5y2M+85rfPOc77/nPgz70okdFCAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PT: prothrombin time; aPTT: activated partial thromboplastin time; vWD: von Willebrand disease; HMWK: high molecular weight kininogen; DIC: disseminated intravascular coagulation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20430=[""].join("\n");
var outline_f19_60_20430=null;
var title_f19_60_20431="Retroperitoneoscopic unilateral adrenalectomy position";
var content_f19_60_20431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Retroperitoneoscopic unilateral adrenalectomy position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the optimal position of the patient on the operating room table &nbsp;for a unilateral retroperitoneascopic adrenalectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_60_20431=[""].join("\n");
var outline_f19_60_20431=null;
